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ABSTRACT 
 
Major depressive disorder (MDD) is characterized by reduced activation of the 
dorsolateral prefrontal cortex (DLPFC), a brain region involved in both emotion 
regulation and basic cognitive control processes.  Recent studies have indicated that 
computerized interventions designed to activate the DLPFC can reduce depressive 
symptoms.  The current study was a randomized controlled trial which extends this 
research to test whether one such program, called Cognitive Control Training (CCT), 
enhances depression treatment outcomes when used in adjunct to brief behavioral 
activation therapy for depression (BATD), an empirically-supported outpatient 
intervention.  This study also explored whether the effects of BATD + CCT treatment on 
depression were mediated by changes in rumination and cognitive control.  In a sample of 
thirty-four adults diagnosed with MDD, participants were randomly assigned to complete 
four sessions of either computerized CCT or a non-active computerized control task, 
concurrently with four sessions of BATD.  Completion of the assigned computerized task 
took place immediately before each of the four BATD therapy sessions.  Depression 
symptoms and proposed treatment mediators were assessed at baseline, mid-treatment, 
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post-treatment, and four-week follow-up visits.  I hypothesized that compared to the 
control group, participants receiving adjunctive CCT would demonstrate significantly 
reduced depressive symptoms.  I also hypothesized that these effects would be mediated 
by changes in inhibitory control and set-shifting performance in the context of negative 
emotional material, as well as by changes in ruminative brooding.  Results did not 
support these hypotheses.  Depressive symptoms were reduced over time in both 
treatment conditions, with no significant difference between treatment conditions.  
Assignment to CCT was not associated with changes in the proposed mediators.  
Furthermore, exploratory analyses found minimal evidence that performance on 
inhibitory control and set-shifting tasks were related to baseline clinical characteristics 
(such as depression severity, rumination, or anxiety symptoms) or treatment outcomes.  
The results of this study support the potential for BATD as a brief, low-cost, flexible 
intervention for the treatment of depression and further show that CCT administered in 
adjunct to a 4-session BATD program does not add clinical benefit in the treatment of 
depression.  This study and other recent research suggest that the effects of CCT may not 
be as robust as previously indicated, highlighting the need for continued investigation of 
the conditions under which CCT may be effective. 
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INTRODUCTION 
 Major Depressive Disorder (MDD) is a highly prevalent disorder that places 
significant burden on society and those suffering from the illness.  Individuals who 
struggle with depression face significant disability including reduced rates of 
employment and productivity (Stewart, Ricci, Chee, Hahn, & Morganstein, 2003), 
increased risk of mortality (Rovner et al., 1991) and suicide (Chen & Dilsaver, 1996), 
social stigma (Cooper, Corrigan, & Watson, 2003; Corrigan, Markowitz, Watson, 
Rowan, & Kubiak, 2003), and interpersonal problems (Burns, Sayers, & Moras, 1994; 
Gotlib & Whiffen, 1989).  The course of depression is relapsing, and each episode further 
denotes an increased risk for another depressive episode (Solomon et al., 2000).  
Furthermore, residual symptoms following treatment are predictive of relapse, making 
full, sustained recovery an important target for treatments (Cornwall & Scott, 1997; Fava, 
Ruini, & Belaise, 2006).  Pharmacotherapy and psychosocial interventions such as 
cognitive therapy and behavioral activation therapy have shown efficacy in the treatment 
of depression, and the recent success of brief behavioral activation protocols across 
depressed populations (e.g., Lejuez, Hopko, Acierno, Daughters, & Pagoto, 2011) have 
shown particular promise for increasing efficiency and access to treatment.  However, 
one concern is that the value of such interventions may be derailed by the ongoing 
negative ruminative style common to patients struggling with depression.   
 MDD is characterized by excessive rumination and difficulties disengaging from 
negative emotional material (for reviews, see Gotlib & Joormann, 2010 and Nolen-
Hoeksema, Wisco, & Lyubomirsky, 2008). For instance, a patient with depression may 
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overly attend to the meaning and the consequences of his or her emotional experience 
(“My mood is so low” or “How did things get this bad?”).  This repetitive yet passive 
focus on one’s inner experience leads individuals to recall more negative memories, 
interpret current situations in a negative way, and to have more pessimistic beliefs about 
the future (Nolen-Hoeksema, 2000).  Research suggests that self-focused, ruminative 
response styles are associated with poorer treatment outcome in MDD (Ciesla & Roberts, 
2002; Schmaling et al., 2002).  Furthermore, ruminative response styles are predictive of 
the onset of a major depressive episode (Abela & Hankin, 2011), longer episodes of 
depression (Abela & Hankin, 2011; Nolen-Hoeksema, Morrow, & Frederickson, 1993), 
suicide ideation (Miranda & Nolen-Hoeksema, 2007), and relapse following treatment 
(Michalak, Holz, & Teismann, 2011).  Closer examination of the construct of rumination 
has led to differentiation between ruminative brooding, defined as a more passive self-
focus, and ruminative reflection, defined as a more purposeful and constructive process 
(Treynor, Gonzalez, & Nolen-Hoeksema, 2003).  Depression has been more strongly 
associated with brooding rather than reflection (Joormann, Dkane, & Gotlib, 2006). 
 The clinical features of depression have also been associated with deficits in 
cognitive control abilities such as attentional and inhibitory control. For example, deficits 
in inhibiting negative emotional information from entering working memory are 
indicated by a number of studies involving negative affective priming tasks.  In these 
tasks, participants are asked to respond to a target stimulus in the presence of an 
irrelevant emotional distractor (i.e., a negative emotional word or face).  On a subsequent 
trial, the distractor stimulus becomes the target, and the participant’s delay in response 
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latency is considered to reflect the strength of the negative priming effect.  A number of 
studies using this type of task have indicated that compared with healthy participants, 
dysphoric and depressed individuals exhibit reduced inhibitory capacity for negative 
emotional information (Goeleven, DeRaedt, Baert, & Koster, 2006; Joormann, 2004; 
Joormann, 2006; Joormann & Gotlib, 2010).  Joormann and Gotlib (2010) also found that 
reduced inhibitory control of negative material was associated with a shift toward less 
adaptive emotion regulation strategies such as increased use of suppression and reduced 
use of reappraisal and reflection. 
 Furthermore, depressed individuals have been found to have greater difficulty 
both removing and manipulating negative information from working memory compared 
with control participants (Joormann & Gotlib, 2008; Joormann, Levens, & Gotlib, 2011).  
Accordingly, Holtzheimer and Mayberg (2011) have suggested that the defining feature 
of depression is not the mere presence of negative mood, but rather, the tendency to get 
“stuck in a rut”; that is, to have a tendency to inappropriately enter into and inability to 
disengage with a depressed mood state.  Consistent with this, a recent study of depressed 
individuals indicated an impaired ability to switch between mental representations in 
working memory in response to facial expressions (De Lissnyder et al., 2012).   
 Importantly, the extent of these deficits in inhibiting, manipulating, and removing 
negative emotional information from working memory has been positively associated 
with increased rumination  (Joormann, 2006; Joormann & Tran, 2009; De Lissnyder et 
al., 2012).  Additionally, rumination has been associated with increased attentional bias 
for negative words, even when controlling for severity of depressive symptoms 
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(Donaldson, Lam, & Mathews, 2007). Rumination also appears to disrupt problem 
solving ability.  For example, individuals engaged in a ruminative task, who were then 
instructed to problem-solve, generated lower quality solutions compared to those who 
had previously engaged in a distracting task (Lyubomirsky & Nolen-Hoeksema, 1995).  
Set-shifting ability, another important component of executive control, is also 
compromised.  For example, individuals with higher levels of rumination (Davis & 
Nolen-Hoeksema, 2000), and clinically depressed individuals (Harvey et al., 2004; 
Merriam, Thase, Haas, Keshavan, & Sweeney, 1999) commit more perseverative errors 
on the Wisconsin Card Sorting Task than healthy controls.  
 There is evidence that the impairments in cognitive control and emotion 
regulation common to depression involve abnormalities in activation and connectivity 
within limbic-cortical brain regions.  Neurobiological models, such as those proposed by 
Mayberg (Mayberg, 1997; Mayberg et al., 1999) and Phillips (Phillips, Drevets, Rauch, 
& Lane, 2003), suggest that depression is characterized by dysregulation of two systems: 
(1) a ventral pathway, which is responsible for the identification of emotional stimuli and 
the production of affective states and behaviors and includes the amygdala and limbic 
regions, and (2) a dorsal pathway, which is involved in the effortful control of emotions, 
and includes the prefrontal cortex, hippocampus, and dorsal anterior cingulate gyrus.  
Concerning the first pathway, patients with depression demonstrate hyperactivity in the 
amygdala, thalamus, and ventral regions of the limbic system (Drevets et al., 1992; 
Mayberg et al., 1999) and increased activity in the amygdala following exposure to 
negative emotional stimuli (Siegle, Steinhauer, Thase, Stenger, & Carter, 2002; Siegle, 
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Thompson, Carter, Steinhauer, & Thase, 2007). Concerning the second pathway, 
depressed patients demonstrate reduced activation of the dorsolateral prefrontal cortex 
(DLPFC; e.g., Davidson, 1994; Drevets, 1999; Mayberg et al., 1999; Siegle et al., 2007), 
the region of the brain responsible for the effortful regulation of emotion (e.g., Ochsner et 
al., 2004; Ochsner & Gross, 2008) as well as basic executive control processes such as 
working memory (for review, see Smith & Jonides, 1999). Recovery from depression has 
been associated with increased DLPFC activation (Fales et al., 2009; Mayberg et al., 
2000) and a reduction in amygdala hyperactivation (Mayberg et al., 2000; Sheline et al., 
2001), suggesting that these disruptions are state-specific. Taken together, these findings 
suggest that depression is maintained by “bottom-up” maladaptive activation of ventral 
(and more specifically, limbic) regions, which leads to increased emotional reactivity and 
the presence of negative mood, and “top-down” failure of the dorsal pathway, that is, 
failure to recruit prefrontal control to attenuate this response (Philips et al. 2003).    
Cognitive Control Training 
 Given these neuropsychological findings, Siegle (1999) has proposed that 
enhancement of cognitive control might alleviate depressive symptoms by enhancing top-
down regulation of negative affect. Consistent with this hypothesis, existing empirically 
based psychological treatments for depression use techniques that may increase cognitive 
control.  For instance, cognitive therapy for depression encourages patients to override 
their automatic negative thought processes and instead identify alternative thoughts.  
Mindfulness-based therapies utilize attentional training, such as exercises in which 
patients practice redirecting attention away from ruminative thoughts and toward the 
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present moment.  However, it remains unclear whether these interventions exert their 
effects through increased cognitive control.   
 In order to test more directly whether increasing cognitive control might reduce 
depression, Siegle and colleagues (2007) developed a computerized neurobehavioral 
therapy that directly targets cognitive control processes such as working memory and 
attention.  Called Cognitive Control Training (CCT), this program consists of two 
computerized training tasks designed to activate and strengthen the prefrontal cortex with 
the goal of correcting the hypoactivity apparent in these areas during depressed mood 
states. The first task, the Wells training task, was designed to improve selective attention 
to specific information, and perhaps thereby increase ability to selectively attend away 
from ruminative thoughts (Wells, 2000).  The Wells task asks participants to listen to an 
array of naturalistic sounds and to attend to one sound at a time, switch attention between 
sounds, and count sounds (Siegle et al., 2014).  The second task is a variant of the Paced 
Auditory Serial Addition Task (PASAT; Gronwall, 1977), which is known to specifically 
activate the prefrontal cortex (Lazeron, Rombouts, de Sonneville, Barkhof, & Scheltens, 
2003).  In this version of the PASAT, participants must continuously add serially 
presented digits, thereby requiring holding information in working memory.  In 
combination, one session of CCT takes approximately 30 minutes to complete.  
 Several studies have now shown that CCT significantly reduces depressive 
symptoms.  In the first study by Siegle and colleagues (2007), 31 severely depressed 
patients participating in an intensive outpatient program were randomized to receive 
treatment as usual (medication management, group therapy based on dialectical behavior 
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therapy principles, and milieu therapy) or treatment as usual plus six sessions of CCT 
over a two-week period.  At post-treatment, participants in the CCT condition 
demonstrated significantly reduced scores on the Beck Depression Inventory (d = 1.28) 
and the Response Styles Questionnaire, a self-report measure of rumination (d = 1.26).  
Moreover, six participants in the CCT condition completed fMRI assessment at pre- and 
post- treatment.  Results showed that following CCT, these participants demonstrated 
increased DLPFC activity on a novel cognitive task, as well as reduced disruption in 
amygdala activity during an emotional responding task.  These findings suggest that CCT 
can effectively reduce symptom severity in severely depressed patients and provide initial 
support for the validity of CCT’s proposed mechanisms of change.    
 In a second study, Calkins and colleagues (2014) examined the effects of CCT in 
a community sample of depressed adults. Forty-eight non-treatment seeking adults with 
depressed mood (as defined by a BDI score ≥ 17) were randomized to 3 sessions of CCT 
or a control task (peripheral vision training, or PVT) over a 2-week period. Participants 
who received CCT experienced a mean reduction of 6 points on the BDI, a significant 
difference (d = 0.73) from the comparison group, whose mean reduction was less than 1 
point.  These results suggest that the benefits of CCT generalize to less severely 
depressed samples and may emerge after a low dose. 
Recently, two studies have examined CCT in combination with transcranial direct 
current stimulation (tDCS), a form of neurostimulation that, when applied to the left 
DLPFC, shows positive yet modest effects on depression symptom severity.  Both studies 
provide more modest estimates of the benefit of CCT in reducing depressive symptoms.  
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In the first study, Segrave and colleagues (2013) compared the efficacy of three treatment 
conditions: tDCS + CCT, sham tDCS + CCT, and tDCS + sham CCT.  Treatment 
sessions occurred daily for 5 days; following this period all groups demonstrated 
significant reductions in depression symptoms.  At a three-week follow-up, only the 
tDCS + CCT group demonstrated a sustained effect, suggesting that CCT alone did not 
lead to sustained gains.  This is important because despite the positive effects 
demonstrated in Calkins et al. (2014), the study was limited by the lack of a follow-up 
assessment period.  A second tDCS study compared depressed participants receiving 10 
sessions of CCT + tDCS vs. CCT + sham tDCS over a 2-week period (Brunoni et al., 
2014).  Both groups of participants demonstrated clinical improvement at the end of 
treatment, however, the response rate was quite low in both conditions (25% across 
groups).  Exploratory analyses indicated that CCT was more effective for older 
participants and participants who performed better on the CCT task throughout the study 
(Brunoni, et al., 2014). 
 These data show some promise for CCT as a mood enhancing intervention but 
suggest that continued study of the intervention is necessary.  It is particularly important 
to continue to investigate the effects of CCT across a range of clinical contexts.  
Although CCT was designed as an adjunctive intervention, it has only been tested in 
adjunct to intensive outpatient (pharmacologic and psychosocial; Siegle, Ghinassi, & 
Thase, 2007) or biological (tDCS; Segrave et al., 2013; Brunoni et al., 2014) treatment 
for depression.  One question of particular interest, then, is whether CCT might enhance 
treatment outcomes when used in adjunct to an empirically-supported psychosocial 
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intervention delivered to outpatients, boosting the efficacy of treatment in an efficient, 
low cost, and transportable manner.   
 A second question pertains to the mechanisms of change of CCT.  Siegle’s initial 
investigation of CCT showed that it led to apparent normalization of activity in the left 
amygdala and left DLPFC during an emotional task.  However, this analysis was only 
conducted in six individuals who received CCT, and the lack of control group and small 
sample size limits the conclusions that can be drawn.  In addition, it remains unclear if 
CCT enhances cognitive control, and if so, what specific cognitive processes are affected.  
Siegle and colleagues (2007) attempted to assess this question using a digit span task, but 
found that all participants performed at ceiling prior to receiving CCT.  Given that 
depressed participants have tended to show impaired inhibitory control and set-shifting 
performance specifically in the context of emotional stimuli, these variables may be 
mediators of CCT effects on depression symptoms.  It is also possible that by enhancing 
cognitive control, CCT allows for improved engagement in psychosocial treatment. For 
example, Addis and Carpenter (1999) found that higher levels of rumination were 
associated with less positive reactions to action-oriented depression treatment rationales.  
Accordingly, in the present study I examine whether adjunctive treatment with CCT 
results in differential improvement in inhibitory control and set-shifting, reductions in 
rumination, and whether these changes are associated with enhanced treatment outcome 
as well as homework adherence. 
Behavioral Activation Treatment for Depression 
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 The current study examines the effect of CCT in adjunct to brief behavioral 
activation treatment for depression (BATD).  Behavioral activation (BA) therapy 
developed out of the behavioral models of depression postulated by Ferster (1973) and 
Lewinsohn (1974) which suggested that depression is maintained by a low rate of 
behavior, which itself is maintained by a lack of positive reinforcement from the 
environment. From this theoretical basis, researchers began to develop interventions 
involving the monitoring and scheduling of reinforcing activities, referring to these 
strategies as activity scheduling.  Several early studies found that activity scheduling 
reduced depression (Lewinsohn, Sullivan, & Grosscup, 1980; Barrera 1979), resulting in 
the inclusion of activity scheduling in a number of treatment packages for depression, 
including Beck’s cognitive therapy and the Control your Depression protocol (Beck, 
1979; Lewinsohn, Munoz, Youngren, & Zeiss, 1978).  Yet attention to these strategies as 
a stand-alone treatment was modest throughout the 1980s and early 1990s.  This changed 
following a seminal study by Jacobson and colleagues (1996) that compared a full course 
of cognitive therapy to activity scheduling (given the label of behavioral activation) and 
automatic thought retraining alone.  Results revealed that behavioral activation alone was 
equally efficacious to the complete cognitive therapy treatment package.  
 Since this time, interest in behavioral activation as a stand-alone treatment has 
grown significantly (for review, see Dimidjian, Barrerra, Martell, Munoz, & Lewinsohn, 
2011).  Behavioral activation protocols for depression have been developed and tested by 
a number of different research groups; although these protocols differ in a number of 
ways, they are alike in that they are grounded in behavioral theories of depression and 
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exclusively target behavior change.  Treatment is structured and goal-directed, and aims 
to engage patients in adaptive, rewarding activities and to reduce involvement in 
behaviors that maintain depressive symptoms (Dimidjian et al., 2011).  To this end, 
primary treatment strategies include self-monitoring of daily activities and mood, 
scheduling of activities that bring patients a sense of pleasure or mastery, and identifying 
and reducing avoidance behaviors that increase depressive symptoms.   
 Several BA protocols have been shown to be efficacious in the treatment of 
severe depression, with one large randomized controlled trial finding that a 24-session 
protocol performed comparably to antidepressant medication and outperformed cognitive 
therapy of a similar length (Dimidjian et al., 2006).  BA is considered to have “strong 
research support” by the APA Presidential Task Force on Evidence-Based Practice 
(2006), and has demonstrated clinically significant positive effects across a range of 
clinical settings and treatment groups, including adult and elderly patients, psychiatric 
inpatients, depressed women with breast cancer, cigarette smokers, and illicit drug users 
(Daughters et al., 2008, Dimidjian et al., 2006; Hopko, Lejuez, LePage, Hopko, & 
McNeil, 2003; Hopko, Bell, Armento, Hunt, & Lejuez, 2005; Macpherson et al., 2010).   
 The current study makes use of a specific BA protocol developed by Lejuez and 
colleagues (2011) called the Brief Behavioral Activation Treatment for Depression 
(BATD).  This time-limited protocol is limited to treatment components related to 
behavioral activation and focuses on monitoring and scheduling activities within a 
values-based framework (Lejuez, Hopko, Acierno, Daughters, & Pagoto, 2011).  Several 
trials provide support for the efficacy of BATD.  Hopko and colleagues (2003) found that 
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compared to treatment as usual, BATD significantly reduced depression symptom 
severity in an inpatient psychiatric sample.  A more recent randomized controlled trial 
demonstrated that the BATD protocol significantly reduced depression and increased 
quality of life and social support among breast cancer patients with major depressive 
disorder, and that these clinical gains were maintained over a twelve-month period 
(Hopko et al., 2011).  A randomized clinical trial examining the addition of BATD to 
standard tobacco cessation techniques in mildly depressed smokers found that the 
addition of BATD resulted in significantly reduced depressive symptoms and enhanced 
smoking abstinence (MacPherson et al., 2010).  
 One of the strengths of the BATD protocol is that it is adaptable to various 
treatment lengths and has shown clinical benefit in very brief protocols.  For instance, 
Daughters and colleagues (2008) found that a six-session BATD treatment for illicit drug 
users significantly reduced depressive symptoms.  More recently, a compacted single 
session of BATD followed by two weeks of activity assignments was found to have a 
large effect (d = 1.61) on the reduction of depressive symptoms in undergraduate students 
compared with a no-treatment control condition (Gawrysiak, Nicholas, & Hopko, 2009).    
 Despite the empirical support for BATD and its clinical advantages such as 
brevity and flexibility, there is room for improvement using this approach.  Even in the 
study with the highest response rates to a full-length BA treatment, 25% of patients did 
not respond to treatment (Dimidjian et al., 2006).  There is likely even greater need to 
improve on brief BATD treatments, which have been found to significantly reduce 
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depressive symptoms but typically result in smaller changes compared to lengthier 
treatments (Daughters et al., 2008; Magidson et al., 2011; Dimidjian et al., 2006).   
 In sum, the reliable evidence for the efficacy of BATD, as well as its brevity and 
flexibility, make it an ideal platform from which to study the additive effects of CCT.  
BATD is a parsimonious treatment that can be effectively applied by non-specialists with 
little training in psychotherapy (Ekers, Richards, McMillan, Bland, & Gilbody, 2011).  In 
addition, there is research suggesting that it may be amenable to computerized or other 
non-traditional treatment formats (Dimidjian et al., 2011), and recent trials of Internet-
based BA packages show initial support for their feasibility and efficacy (Carlbring et al, 
2013; O’Mahen et al., 2013).  BATD is a primarily behavioral intervention, providing an 
appropriate backdrop in which the added effects of the cognitively focused CCT program 
may be evaluated.  The addition of CCT as an adjunct to brief BATD provides an easily 
transportable cognitive component that is not included in the behaviorally-focused BATD 
protocol.   
The Current Study 
 This investigation expands upon previous trials of CCT for depression by testing 
its efficacy in adjunct to BATD and by examining proposed mediators of treatment.  
Twenty-six individuals with a primary diagnosis of MDD received 4 sessions of BATD 
and were randomly assigned to concurrently complete either four sessions of CCT or four 
sessions of a computerized control condition called peripheral vision training (PVT).  
Depression symptoms and hypothesized mediators of treatment outcome were assessed at 
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pre-, mid-, and post-treatment and at a four-week follow-up.  The aims and hypotheses 
were as follows:    
 Aim 1, Hypothesis 1.  To test whether adjunctive CCT adds significant clinical 
benefit to BATD.  I hypothesized that relative to those in the BATD + PVT condition, 
individuals in the BATD + CCT condition would demonstrate greater reduction in 
depression symptoms and that this effect would be maintained over the four-week follow-
up period.  
 Aim 2, Hypothesis 2. To examine changes in ruminative brooding, cognitive 
control of emotional material, and homework compliance as potential mediators of 
response to CCT.  I hypothesized that relative to the BATD + PVT condition, the BATD 
+ CCT condition would be associated with reductions in rumination and increased 
cognitive control.  Further, I hypothesized that these variables would mediate the 
relationship between treatment condition and treatment outcome and the relationship 
between treatment condition and BATD homework adherence.  
METHODS 
Design 
 Participants received four weekly sessions of BATD and were randomly assigned 
to concurrently receive four sessions of CCT or four sessions of PVT during the same 
period.  Treatment outcome was assessed by self-report and clinician-rated depressive 
symptom rating scales, with secondary outcomes of self-reported rumination and anxiety 
symptoms.  Cognitive control (specifically, inhibitory control and set-shifting), 
environmental reward, and homework adherence were assessed at baseline, midpoint, 
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post-treatment, and 4-week follow-up in order to evaluate potential mediators of 
treatment response.  The design was double-blind, such that participants and the 
independent evaluators assessing depression severity were not informed of the 
randomized portion (CCT vs. PVT) of the treatment.  The trial was registered with 
clinicaltrials.gov with identifier NCT01694719.  
Participant Enrollment  
 Participants were recruited between October of 2012 and April of 2014 through 
community advertisements or were referred from the Center for Anxiety and Related 
Disorders at Boston University.  Potential participants were screened via telephone 
interview before being invited to an in-person screening visit. The inclusion/exclusion 
criteria were as follows: 
Inclusion Criteria:   
1. Between 18 and 65 years of age 
2. Primary psychiatric diagnosis of major depressive disorder 
3. Ability to read and speak English sufficiently to complete study procedures 
4. If taking antidepressant or anxiolytic medication, participants must be taking a 
stabilized for a minimum period of at least 8 weeks prior to entry into the study 
5. Willingness and ability to comply with the requirements of the study protocol 
Exclusion Criteria:  
1. Lifetime history of bipolar disorder or psychotic disorder as assessed by SCID-IV 
or ADIS-IV-L 
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2. Neurological disorder such as Parkinson’s disease or traumatic brain injury as 
assessed by patient self report during the phone screen and again during the 
screening visit 
3. Alcohol or substance dependence within the past 6 months as assessed by SCID 
or ADIS-IV-L 
4. Substantial suicide risk, as indicated by a rating of 2 or greater on the suicide item 
of the BDI 
5. Concurrent psychotherapy initiated within 2 months of baseline, or ongoing 
psychotherapy of any duration directed specifically toward treatment of the 
depression other than general supportive therapy  
6. Current use of antipsychotics, stimulants, or modafinil 
 Figure 1 provides a CONSORT diagram representing the flow of participants 
through the trial.  Following telephone pre-screening interviews, 43 participants attended 
the screening visit in which they provided informed consent and were administered the 
SCID-IV to assess eligibility.  Six individuals did not meet criteria for study entry (3 did 
not meet diagnostic criteria for MDD, 2 had bipolar disorder, and 1 did not have a 
principal diagnosis of MDD).  Of the 37 participants deemed eligible after the screening 
visit, 3 were lost to follow up prior to randomization and initiation of treatment.   
Randomization 
 The remaining 34 participants were randomly assigned to CCT or PVT 
conditions.  The randomization sequence was generated by the author using a 
computerized random number generator service.  Randomization was stratified by 
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severity of depression, where a BDI score greater than 29 was considered severe 
(consistent with the clinical severity ranges of the BDI; Beck, Steer, & Brown, 1996).   
Due to a disproportionate attrition rate (a greater number of individuals in the CCT 
condition failed to complete the study), the randomization schedule was modified 
halfway through the trial in order to ensure an equal number of completers in each 
condition.  
Measures 
 Diagnosis.  The Structured Clinical Interview for Axis I Disorders for DSM-IV 
(SCID-IV; First, Spitzer, Gibbon, & Williams, 2002) was used to assess the presence of 
MDD at the initial study visit and to rule out other diagnoses that would preclude 
participation in the study, such as a psychotic disorder or bipolar disorder.  Individuals 
referred through the Center for Anxiety and Related Stress Disorders had already 
received a diagnostic interview using the Anxiety Disorders Interview Schedule for 
DSM-IV, Lifetime Edition (ADIS-IV-L; Brown, DiNardo & Barlow, 1994); therefore, 
the depression module of the SCID was repeated to reconfirm the diagnosis of MDD, but 
the entire SCID was not repeated.  DSM-5 (American Psychiatric Association, 2013) was 
not published until after the completion of the study; however, post-hoc review showed 
that all patients included in the study would have also met criteria for MDD based on 
DSM-5 criteria. 
 Primary outcomes: depression symptom severity.  The Beck Depression 
Inventory-II (BDI; Beck et al., 1996) was used to assess self-reported depression 
symptom severity.  The BDI is a well-validated self-report measure of depressive 
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symptom severity.  It consists of 21 items rated on a 4-point Likert scale and assesses a 
range of psychological and somatic symptoms of depression.  The BDI has been well 
studied over the past several decades and is sensitive to change and discriminates well 
between depressed and non-depressed individuals (Beck, Steer, & Garbin, 1988; Richter, 
Werner, Heerlein, Kraus, & Sauer, 1998).  Correlations with clinician-rated measures of 
depression severity such as the Montgomery-Asberg Depression Rating Scale and the 
Hamilton Depression Rating Scale range from r = .35 (Schotte, Maes, Cluydts, Doncker, 
& Cosyns, 1997) to r = .77 (Uher et al., 2008).  The BDI was used as the primary 
outcome measure and was assessed at each study visit.  At Weeks 2, 3, and 4, a modified 
version of the BDI was used that assessed symptoms over the past one week instead of 
the past two weeks.   
 The Montgomery-Asberg Depression Rating Scale (MADRS; Montgomery & 
Asberg, 1979) was used as the clinician-rated measure of depression. This 10-item 
interview measures the following disturbances:  sadness, tension, sleep, appetite, 
concentration, lassitude, numbness, pessimism, and suicidal ideation.  The MADRS has 
demonstrated clinical sensitivity in antidepressant clinical trials and has demonstrated 
good reliability and concurrent validity with other commonly used clinician-rated 
measures of depression such as the Hamilton Depression Rating Scale (Davidson, 
Turnbull, Strickland, Miller, & Graves, 1986; Khan, Khan, Shankles, & Polissar, 2002).  
The MADRS was administered by independent evaluators blind to treatment condition 
(CCT or PVT); raters were graduate students.  The evaluators were trained on the 
measure via training with the PI and videotape training.  The MADRS was used as a 
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secondary outcome measure and was assessed at baseline, post-treatment, and follow-up 
visits.   
Rumination.  Rumination was assessed with the Ruminative Response Scale 
(RRS; Nolen-Hoeksema & Morrow, 1991).  The RRS is a 22-item self-report measure 
assessing the tendency to ruminate in response to sad mood.  The scale is rated on a 4-
point Likert scale; higher scores reflect greater tendency to ruminate.  The RRS contains 
two factor-derived subscales: Brooding and Reflective Pondering (Treynor et al., 2003).  
Studies of these subscales suggest that brooding is strongly associated with maladaptive 
emotional outcomes and that reflection may be a more adaptive process (Treynor et al., 
2003; Joormann, 2006); however, some research suggests that these two constructs may 
be less distinguishable in clinically depressed samples (Whitmer & Gotlib, 2011).  The 
RRS has been well-validated in depressed, anxious, and clinically healthy samples (e.g., 
Nolen-Hoeksema & Morrow, 1991; Nolen-Hoeksema, Morrow, & Fredrickson, 1993; 
Butler & Nolen-Hoeksema, 1994). The RRS was assessed at baseline, mid-point, post-
treatment, and follow-up visits. 
Environmental reward.  The Reward Probability Index (RPI; Carvalho et al., 
2011) is a self-report measure designed to assess environmental reward as a way of 
approximating response-contingent positive reinforcement.  The scale consists of 20 
items and is rated on a 4-point Likert scale, with higher scores indicating greater levels of 
environmental reward.  The RPI has two subscales: Reward Probability and 
Environmental Suppressors.  The  Reward Probability subscale items relate to the number 
of potential reinforcers and the individual’s ability to engage in instrumental behaviors 
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(Carvalho et al., 2011; for instance “I make friends easily” or “I consider myself to be a 
person with many skills”).  The Environmental Suppressors subscale items relate to the 
presence of aversive environmental stimuli (Carvalho et al., 2011; for instance, “My 
behaviors often have negative consequences” or “I have few financial resources, which 
limits what I can do”).  The RPI has been shown to correlate strongly with measures of 
depression, activity, and pleasurable events (Carvalho et al., 2011).  It also demonstrates 
good test-retest reliability and discriminant validity from social support and somatic 
anxiety (Carvalho et al., 2011).  The RPI was administered at baseline, mid-point, post-
treatment, and follow-up visits.  
 Anxiety symptoms.  The Beck Anxiety Inventory (BAI; Beck & Steer, 1993) is a 
commonly used 21-item self-report inventory designed to measure severity of anxiety 
symptoms.  The measure demonstrates high internal consistency and concurrent validity 
with other assessments of anxiety in psychiatric outpatient populations (e.g., Steer, 
Ranieri, Beck, & Clark, 1993).  The BAI was assessed at baseline, post-treatment, and 
follow-up visits. 
 Homework compliance.  Homework compliance was rated at sessions 2-5 of the 
behavioral activation treatment. Ratings for Weeks 3 - 5 were made by the therapist and 
were based on a coding system developed by Busch and colleagues (2010). This system 
is the first developed specifically to measure homework compliance in BA treatments, 
and assesses the type of assignment (e.g. single activity, repeated activity), realm of 
functioning, difficulty level, and extent of completion.  Therapists rate the patient’s 
completion of an activity on a percentage scale (0 – 100% completion) and a categorical 
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scale (3 = fully completed, 2 = partial completion, 1 = made attempt/effort to start, 0 = 
made no effort to begin assignment). Busch and colleagues (2010) determined that the 
use of this coding system had a high level of inter-rater agreement and found that 
homework completion ratings were strongly correlated with treatment change scores (r = 
.47 and r = .55 respectively for percent completion and categorical completion ratings).   
Because activity assignments were not assigned before the second session, adherence at 
Week 2 was rated on a Likert-type scale reflecting the extent to which the activity-
monitoring assignment was completed (0 = no completion, 3 = moderate completion, 6 = 
completed all assignments and brought in written forms). 
Cognitive Control Tasks 
 NAP Task: Inhibition of emotional processing.  The Negative Affective 
Priming (NAP) task is a computerized negative priming task which assesses inhibition in 
emotional processing (Joormann, 2004). In the NAP task, participants are asked to 
respond to a target stimulus in the presence of an irrelevant emotional distractor (i.e., a 
negative emotional word).  On a subsequent trial, the distractor stimulus becomes the 
target, and the participant’s delay in response latency is considered to reflect the strength 
of the negative priming effect (with a slower response time reflecting stronger inhibitory 
control).  Participants with higher levels of depressive or ruminative symptoms tend to 
demonstrate reduced inhibition of negative material.  That is, compared to euthymic or 
low-ruminating individuals, they are quicker to respond to a negatively-valenced target 
that had been the distractor stimulus in the previous trial.  Joormann et al. (2010) 
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developed the NAP task used in the current study; the task stimuli and procedures are 
described in detail in Joormann et al. (2010) and are included below for reference.   
Stimuli.  NAP task stimuli consisted of 56 positive, 56 negative, and 16 neutral 
words.  Words were adjectives chosen based on their positive, negative, or neutrally 
valenced ratings on the Affective Norms for English Words list (Bradley & Lang, 1999).  
E-prime Psychology Software Tools Inc. version 1.0 software was used to run the task.  
Procedure and scoring. The NAP task consists of consecutive pairs of trials: a 
prime trial and a test trial.  In each trial, two adjectives are presented simultaneously on 
the upper and lower halves of the screen, one word in red and one word in blue.  
Participants are instructed to always ignore the word in red (the distractor) and to respond 
to the word in blue (the target) by pressing a key to indicate whether the blue word is 
positive or negative.  Participants are not aware of the distinction between a prime or a 
test trial.  Sets of trials are categorized as either “negative priming” trials or “control” 
trials.  During a negative priming trial, the distractor in the prime trial shares the same 
valence as the target in the subsequent test trial.  Therefore, in this condition, the 
participant’s response to the target in the test trial should be delayed if inhibition of the 
distractor from the previous prime trial is still activated.  During a control condition trial, 
the distractor in the prime trial does not share the same valence as the target in the test 
trial, and is a neutral word.  Examples of negative priming and control trials are presented 
in Figures 2 and 3. 
 Participants completed 10 practice trials before completing the full task, which 
consisted of 5 blocks of 64 prime and test trials (320 trials).  The task took approximately 
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15-20 minutes to complete.  The words were randomly selected from the word list for 
each participant, as were the trial sequences within each of the five blocks.  The position 
of the target and distractor words on the screen (upper vs. lower half) was also randomly 
assigned.  In between each trial, a fixation cross appeared on the center of the screen for 
500 ms.   The words were separated by 2 cm and each letter was approximately 2 cm in 
size.  Reaction times and responses were recorded, and participants were instructed to 
respond to the target word as quickly and as accurately as possible. Only the responses to 
the test trials (as opposed to the prime trials) were analyzed.   
 Trials in which the participant responded inaccurately were excluded from 
analysis, as were trials with outlier response times of < 300 or > 2000 ms (Joormann et 
al., 2010).  Mean response time scores were calculated for four trial conditions: negative 
priming for negative words, negative priming for positive words, and control trials (for 
negative and positive words).  Additionally, bias scores were calculated for each 
individual by subtracting the control RT from the negative priming RT (individually for 
negatively and positively valenced words; Joormann, 2004). 
 Internal Shift Task: Attentional shifting.  The Internal Shift Task (IST) is a 
computerized task that assesses the ability to switch attention between items in working 
memory in response to emotional and non-emotional facial expressions (De Lissnyder et 
al., 2012; Demeyer, De Lissnyder, Koster, & De Raedt, 2012). The IST has been shown 
to have high internal consistency and test-retest reliability (De Lissnyder, Koster, & De 
Raedt, 2012), and has previously been shown to be associated with worry (Beckwe, 
Deroost, Koster, De Lissnyder, & De Raedt, 2013), rumination (De Lissnyder, Koster, & 
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De Raedt, 2012), and dysphoric mood (DeMeyer, De Lissnyder, Koster, & De Raedt, 
2012)  However, to my knowledge, depression treatment effects on IST performance 
have not been evaluated. 
 IST stimuli and procedures.  Stimuli and procedures are identical to De Lissnyder 
et al. 2012.  The 24 neutral and 24 angry face images were taken from the Karolinska 
Directed Emotional Faces stimuli (Lundqvist, Flykt, & Öhman, 1998), and more 
specifically, from a validation study of the picture set (Goeleven, De Raedt, Leyman, & 
Verschure, 2008). E-prime Psychology Software Tools Inc. version 2.0 software was 
used to run the task. 
 During the IST, participants complete two blocks of emotion and gender 
condition trials as described above.  The order of the two blocks is randomly assigned by 
the computer program. In each block, participants complete 12 trials in which 10-14 face 
images were presented on the screen one at a time.  Three practice trials precede each 
block of 12 experimental trials.  Participants are instructed to keep a silent mental count 
of the number of faces they see in each category (angry vs. neutral for the emotional 
condition, and female vs. male for the gender condition).  When a face appears on the 
screen, they must mentally categorize it (adding it to the existing count of faces) and must 
press the spacebar as quickly as possible to indicate that they have added that face to the 
mental count.  At the end of each trial, participants report the number of faces from each 
category as a marker of accuracy.   
 In addition to block condition (emotion vs. gender), trials can be categorized as 
switch or no-switch trials.  A switch trial occurs when the image shown in the trial is of a 
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different category than the preceding image (for instance, a switch from a neutral to an 
angry face in the emotion condition, or a switch from a female to a male face in the 
gender condition).  A no-switch trial occurs when the image shown in the trial does not 
change category from the preceding trial (for instance, a neutral face followed by a 
neutral face in the emotion condition, or a male face followed by a male face in the 
gender condition).  This allows for a calculation of “switch cost”: the difference in 
average reaction time in a switch trial compared to a non-switch trial (of the same 
condition).  Therefore, IST performance can evaluate general switching capacity (switch 
cost across both emotion and gender condition), switching capacity for emotional 
compared to non-emotional material, and switching capacity for specific types of 
emotional information (angry to neutral, neutral to angry, neutral to neutral, or angry to 
angry).   
 Median reaction time scores were used for data analyses in order to reduce outlier 
influence.  Both correct and incorrect blocks of items were included in analyses, 
consistent with previous studies (De Lissnyder, Koster, & De Raedt, 2012).  
Procedures 
 A table depicting the study measures and procedures at each visit is presented in 
Table 1.  Following the screening visit, eligible participants received baseline assessment, 
were randomized to treatment condition, and began four weekly sessions of BATD. CCT 
and PVT exercises were completed in the laboratory immediately prior to each BATD 
session. Posttreatment assessment took place one week after the fourth and final 
treatment session (at Week 5). Follow-up assessment took place four weeks following the 
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final treatment session (Week 8).  Following final assessment (at the same visit) a booster 
session of BATD was offered.  Participants were encouraged to attend the assessment 
visits in person but were offered the option of completing assessments by telephone if 
necessary. The total duration of study participation for each patient was approximately 
nine weeks.  Participants were paid $40 for the completion of the posttreatment and 
follow-up assessments, for a total of $80.  
Treatment 
BATD.  Behavioral activation treatment was adapted from the BATD protocol 
described by Lejuez et al. (2011).  This brief protocol has been shown to reduce 
depressive symptoms in a number of randomized control trials across a range of 
depressed patient groups, including adult inpatients, individuals in treatment for illicit 
drug use, and patients with breast cancer (Daughters et al., 2006; Hopko et al., 2003, 
Hopko et al., 2011).  The current study utilized a four-session version of the protocol 
modified from a previous trial which demonstrated positive effects of a five-session 
protocol (Magidson et al., 2011).  Most efficacy studies of BATD protocols have ranged 
from 5 to 12 sessions in length (e.g. Magidson et al., 2011; Lejuez et al., 2011).   I chose 
to utilize a four session protocol in order to be consistent with the brief time frame of 
CCT, which to date has been studied in limited doses within one or two-week periods.  
The use of this brief protocol is also appropriate for testing the ability of CCT to add 
benefit to BATD and enhanced the feasibility of the study.  An outline of the brief 
protocol used in the current study is described as follows:   
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Session 1: Psychoeducation for depression, introduction to treatment rationale and 
activity monitoring; discussion and identification of patient’s values across different life 
areas (relationships, occupation/education, recreation, spirituality, etc.) and activities that 
reflect these values. 
Session 2: Review activity monitoring and valued activities assignment, begin activity 
planning. 
Session 3: Review activity monitoring and planning and generate new plan for the next 
week.  Introduce contracting with friends and family to receive needed support when 
depressed. 
Session 4: Review activity monitoring and scheduling and generate new plan for next 
week.  Prepare for end of treatment. 
 Therapists completed a comprehensive four-hour training in the BATD protocol 
by Dr. Carl Lejuez, followed by weekly supervision from a licensed clinical psychologist 
with expertise in the protocol throughout the treatment period.  Treatment was provided 
by two doctoral students in psychology.  Treatment adherence was monitored with an 
adherence checklist which therapists self-rated following each session to indicate whether 
the core strategies and topics were covered.  
Computerized Experimental Tasks:  
The active and control versions of the computerized training tasks are described 
below.  Both conditions take approximately 30 minutes to complete and were 
administered immediately before each of the four BATD sessions. 
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 Cognitive Control Training (CCT) Tasks. CCT consists of two tasks 
(completed in the following order): 
 Paced Auditory Serial Addition Task (PASAT; Gronwall, 1977). The PASAT was 
originally developed to assess cognitive recovery follow brain injury, with a focus on 
measurement of sustained attention, flexibility, and auditory information processing 
(Gronwall, 1977).  In CCT, a modified computerized version of the PASAT is used 
(Siegle et al., 2007).  Participants are asked to add aurally presented numbers 
continuously for three five-minute blocks of time.  As each new digit is presented, 
participants must sum it with the digit that was previously presented instead of with the 
participant’s previous answer.  This requires sustained attention to the aurally presented 
numbers as well as inhibition of encoding of their own responses. Participants are 
instructed to respond quickly and accurately, and to return to the task as soon as they 
miss an answer.  Task difficulty is equated across participants by adapting the speed 
based on the patient’s performance.  The task starts with a 3000 ms Inter-stimulus 
Interval (ISI).  The speed is increased by 100 ms for every four correct items in a row, 
and is slowed by 100 ms when a patient misses four consecutive items.  Therefore, the 
average ISI may serve as a marker of task performance. 
 Attention Control Intervention (Wells, 2000). This task was designed to train 
selective attention to specific information and involves training individuals to attend 
differentially to multiple auditory sources (e.g., by counting tones, discriminating the 
location of tones, and moving their attention between auditory sources for a prolonged 
period).  Unlike the PASAT, this task is considered to be “low-load,” and participants 
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must stay focused on the task even when naturally occurring depressive or ruminative 
thoughts occur  (Siegle et al., 2014).  The intervention takes approximately 10 minutes to 
complete. 
 Comparison task.   
Peripheral Vision Task (C. Moore, personal communication). The PVT task 
serves as a non-active control condition which does not target the brain regions 
influenced by the Wells and PASAT tasks. Participants are instructed to focus their eyes 
on a fixation point in the center of the screen, but to move their peripheral vision around a 
series of circles on the outer edges of the screen in response to a series of auditory tones.  
When the sequence of tones ends, they are instructed to indicate the color of the circle 
that they are now attending to in peripheral vision.  The task takes approximately 20 
minutes to complete. 
Power Analysis 
 Effect sizes for CCT have been large in previous investigations of depressed 
individuals.  Compared with a computerized control condition, three doses of stand-alone 
CCT was associated with an effect size of d = .73 in a community sample of adults with 
depressed mood (Calkins, McMorran, Siegle, & Otto, 2014).  In the current study, each 
treatment group received an active treatment, which holds the possibility of reducing the 
between-group differences for the adjunctive interventions.  Therefore, a power analysis 
was conducted anticipating a medium effect size rather than a large one.  A priori power 
analysis using G-Power (version 3.1; Faul, Erdfelder, Lang, & Buchner, 2007) indicated 
that a sample of 26 patients would provide 80% power to detect a medium effect size (F 
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= .25) using repeated measures ANOVA involving six measurement points (BDI scores 
assessed at all six study visits; alpha = .05).   
Statistical Analysis Plan 
 T-tests and Fisher’s exact tests were used to test for baseline differences between 
the randomized treatment groups, informing whether or not patient characteristics should 
be controlled for in subsequent outcome analyses.  Analyses were planned a-priori using 
two methods.  The first and preferred method was latent growth modeling, a structural 
equation modeling approach to examining change over time (LGM; also known as latent 
trajectory modeling or latent curve analysis).  LGM allows for modeling individual and 
between-group differences in trajectories over time and is flexible enough to handle 
partially missing data and unevenly spaced measurement time points (Curran, Obeidat, & 
Losardo, 2010; Duncan & Duncan, 2004; Muthen & Curran, 1997).  Additionally, LGM 
lends itself well to evaluation of mediation effects and the effect of baseline scores on 
change over time (Selig & Preacher, 2009).  Despite these strengths, there is a concern 
regarding the sample size necessary to achieve a model of good fit.  Although some have 
successfully applied LGM to very small samples (for instance, n = 22; Huttenlocher, 
Haight, Bryk, Seltzer, & Lyons, 1991), it is often preferred that sample sizes of over 100 
are used (Curran, Obeidat, & Losardo, 2010).  Additionally, there is no clear rule of 
thumb for estimating the required sample size; according to Muthen & Muthen (2002), 
this depends largely on aspects of the data that are difficult to estimate in a-priori fashion, 
such as data distribution, reliability, the extent of missing data, and the strength of the 
relationships between the variables.  Based on these concerns, I planed to first attempt to 
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fit the study data to a latent growth model, and to proceed using LGM for all study 
analyses if evaluation suggested a good model fit.  Tests of model fit included the root 
mean square error of approximation, Chi Square, and standardized root mean square 
residual. 
 The second planned method for analysis, in the event that LGM proved 
inappropriate, was to use repeated measures ANOVA to examine depressive symptoms 
as functions of the interaction between time and treatment condition.   Fisher’s Exact 
tests would be used to examine differences in the rates of response and remission by 
treatment group.  Secondary analyses were also planned using repeated measures 
ANOVA to examine between-group differences in rumination (RRS), cognitive control 
(NAP and IST), environmental reward (RPI), and homework compliance over time.   A 
treatment by time interaction would indicate that CCT vs. PVT differentially affected 
these potential mediating variables.  If these hypothesized effects were obtained, I 
planned to examine mediation effects using the four-step regression procedures described 
by Baron and Kenny (1986). 
 Treatment outcome analyses were conducted for the sample of completers (n = 
26) and for an intent-to-treat (ITT) sample which included all individuals who were 
randomized to a treatment condition (n = 34).  In the ITT analyses, missing data was 
accounted for by carrying the last observation forward to all subsequent assessment time 
points.  All tests were conducted using a significance level of p < .05.  Effect sizes were 
calculated using Cohen’s d (interpreted as .2 = small, .5  = medium, .8 = large; Cohen, 
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1988) and η2 (interpreted as .02 = small, .13 = medium, .26 = large; Murphy & Myors, 
2004).  
RESULTS 
Sample Characteristics 
 Sample characteristics of participants in the CCT and PVT groups are presented 
in Table 2. The two groups demonstrated no significant differences in age, gender, 
education, race, ethnicity, BDI, RPI, RRS, and MADRS scores, or psychiatric medication 
use.   These results remained consistent when including only the smaller sample of 
treatment completers (n = 26; see Table 3).  There were no significant differences on 
these characteristics between individuals who completed treatment (n = 26) and those 
who dropped out (n = 8; see Table 4). 
 The mean baseline scores on the BDI (M = 29.6, SD = 10.1) and MADRS (M = 
26.6, SD = 7.6) indicate that the overall sample was experiencing moderate to severe 
levels of depression.  Fifty-three percent of the sample had experienced a previous 
episode of depression.  Thirty-five percent (n = 12) of the sample had no comorbid 
psychiatric disorders; 35% (n = 12) had one comorbid disorder; 21% (n = 7) had two 
comorbid disorders, and 6% (n = 2) had three comorbid disorders. The comorbid 
diagnoses were as follows (based on DSM-IV-TR criteria): social phobia (n = 12), eating 
disorder not otherwise specified (n = 3), generalized anxiety disorder (n = 3), 
posttraumatic stress disorder (n = 2), dysthymia (n = 2), body dysmorphic disorder (n = 
1), obsessive-compulsive disorder (n = 1), trichotillomania (n = 1), somatization disorder 
(n = 1), panic disorder with agoraphobia (n = 1), agoraphobia without panic disorder (n = 
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1).  The number of comorbid diagnoses did not differ between the two treatment 
conditions (t (31) = -.93, p = .36). 
 Ten participants were taking psychiatric medications at the time of study 
participation.  The medications were as follows: fluoxetine (n = 2), clonazepam (n = 2), 
amitriptyline (n = 1), atenolol (n = 1), buproprion (n = 1), buspirone (n = 1), citalopram 
(n = 1), clonidine (n = 1), escitalopram (n = 1), eszopiclone (n = 1), gabapentin (n = 1), 
lorazepam (n = 1), paroxetine (n = 1), selegiline (n = 1), sertraline (n = 1), trazodone (n = 
1), and venlafaxine (n = 1). 
Treatment Outcome 
 Means and standard deviations for primary and secondary outcome measures are 
presented in Table 5 (ITT sample) and Table 6 (Completer sample).  When BDI scores 
were entered into a latent growth curve model, indices showed very poor fit (Chi Square 
= 53.96, Root Mean Square Error of Approximation = .256).  Subsequent adjustments to 
the model based on modification indices and standardized residual values did not 
improve model fit.  I therefore proceeded with treatment outcome analyses using repeated 
measures ANOVA. 
 Depression symptoms.  BDI scores decreased significantly over the course of 
treatment, as evidenced by a main effect of time on BDI total score in the ITT sample (F 
(3.29) = 14.01, p = .00, ηp2 = .31) and the completer sample (F (3.30) = 11.91, p = .00, 
ηp2= .34).  Completers demonstrated an average decrease of 11.2 points in BDI score over 
the course of the study.  Concerning Hypothesis 1, there was no main effect of treatment 
condition (all p values > .70), and the interaction between time and condition on BDI 
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scores was non-significant (ITT sample: F (3.29) = 1.63, p = .18, ηp2= .05); completer 
sample: F (3.30) = .97, p = .42, ηp2 = .04).   
 The same pattern of results was found when examining MADRS score as a 
secondary outcome measure of depressive symptoms.  MADRS scores decreased 
significantly over the course of treatment in both the ITT (F (2) = 27.08, p = .00, ηp2 = 
.46) and completer analyses (F (2) = 23.75, p = .00, ηp2 = .51).  No main effect of 
treatment condition was found (all p values > .50), and the time by condition interaction 
was non-significant (Total sample: F (2) = .43, p = .66, ηp2 = .01; completers only: F (2) 
= .36, p = .70, ηp2 = .016). 
 To examine differences in the rates of response and remission by treatment group, 
recommendations by Riedel and colleagues (2010) were followed: treatment response 
was defined as a decrease in BDI score of at least 47%, and remission was defined as a 
BDI score of ≤ 12. When treatment response was examined in the completer sample, 
rates of remission and response were 34.6% and 38.5% respectively.  In the ITT sample, 
rates of remission and response were 26.5% and 29.4%, respectively.  In both the ITT 
and completer samples, rates of remission and response at Weeks 5 and 8 were higher in 
the PVT group; however, the difference was not statistically significant.  Rates of 
response and remission by treatment condition are presented in Table 7.     
Secondary Outcomes 
 Rumination. RRS total scores decreased significantly over time in both the ITT 
sample (F (2.07) = 14.13, p = .00, ηp2 = .31) and the completer sample (F (3) = 13.45, p = 
.00, ηp2 = .38).  There was no main effect of condition on RRS scores (all p values > .30), 
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and, as a direct test of Hypothesis 2, the interaction between time and condition was not 
significant (ITT sample: F (2.07) = 1.63, p = .19, ηp2 = .048; completer sample F (3) = 
.47, p = .71, ηp2 = .02).   
 The brooding subscale of the RRS was examined separately given that it has been 
shown to be more closely related to depression (Schoofs, Hermans, & Raes, 2010) and 
cognitive biases (Bernblum & Mor, 2010; Joormann et al., 2010) than the RRS total 
scale.  RRS-brooding scores decreased significantly over time in both the ITT sample (F 
(2.2)  = 7.93, p = .001, ηp2 = .20) and the completer sample (F (2.2) = 6.47, p = .002, ηp2 = 
.21).  There was no main effect of condition (all p values > .85).  As the core test relevant 
to Hypothesis 2, the interaction between time and treatment condition on RRS-brooding 
was not significant (ITT sample F (2.2) = 2.52, p = .08, ηp2 = .07; completer sample F 
(2.2) = 1.86, p = .16, ηp2 = .07).   
 Environmental Reward. There was a main effect of time on environmental 
reward, with RPI-reward probability subscale scores increasing significantly over the 
course of treatment (ITT sample: F (3) = 14.09, p = .00, ηp2 = .31; completer sample: F 
(3) = 12.23, p = .00, ηp2 = .36).  The effect of condition was not significant (all p values > 
.48).  Relevant to Hypothesis 2, the interaction between time and condition was also not 
significant (ITT sample F (3) = .91, p = .44, ηp2 = .028; completer sample F (3) = 1.11, p 
= .35, ηp2 = .048).   
 RPI-environmental suppressor subscale scores also increased significantly over 
the course of treatment (ITT sample F (2.34) = 6.76, p = .001, ηp2 = .17; completer 
sample F (3) = 4.81, p = .004, ηp2  = .18).  There was no effect of condition on RPI-ES 
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scores (all p values > .28).  The interaction between treatment and condition was non-
significant for both the ITT sample (F (2.34) = 2.27, p = .10, ηp2 = .07) and the completer 
sample (F (3) = 2.03, p = .12, ηp2 = .08).   
Anxiety.  There was a main effect of time on BAI scores, such that BAI scores 
decreased over time (ITT sample F (1.61) = 9.08, p = .001, ηp2 = .24; completer sample F 
(2) = 7.71, p = .001, ηp2 = .27). There was no main effect of condition (all p-values > .70) 
on BAI scores, and the interaction between treatment condition and time was non-
significant in both the ITT sample (F (2) = 1.87, p = .16, ηp2 =.06) and the completer 
sample (F (2) = 1.08, p = .35, ηp2 = .05). 
Treatment Mediation 
 Although there were no significant differences in outcome by treatment condition, 
“the absence of differences between two active treatments does not imply that mediated 
effects are also absent” (Doss et al., 2006). Two equally successful therapies may work 
through different means; behavioral activation therapy outcomes, for instance, might be 
mediated by change in environmental reward, while a cognitive therapy might be 
mediated by change in patients’ cognitions.  Therefore, examination of mediation effects 
may still be informative.  In the current study, variables of theoretical interest include 
cognitive control (IST and NAP task performance), environmental reward (RPI scores), 
rumination (RRS scores), and homework adherence.  Analyses focusing on cognitive 
control are described in more detail in the “NAP task results” and “IST task results” 
sections below.  
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 Consistent with Baron and Kenny’s (1986) recommendations, a key requirement 
for mediation is to show that the independent variable (in this case, treatment condition) 
is significantly associated with the hypothesized mediator.  In bivariate correlational 
analyses including only treatment completers, treatment condition (1 = CCT, 2 = PVT) 
was not significantly associated with the hypothesized mediators – rumination (RRS total 
r = .02, p = .94; RRS brooding r = .21, p = .30), reward probability (RPI reward 
probability  r = .03 p = .89; RPI environmental suppressors r = .14, p = .49), or 
homework adherence rating (r = .03, p = .88) - at treatment midpoint.     
 Given that no significant differences were found between treatment conditions on 
any outcome measure or hypothesized mediator, the two groups were then combined for 
exploratory analyses that might inform further study of predictors and mechanisms of 
BATD. 
Exploratory analyses: What baseline characteristics predict treatment outcome?  
 Hierarchical regression analyses were used to examine the influence of baseline 
characteristics on follow-up BDI scores alone and in interaction with treatment condition.  
Baseline BDI scores were entered in the first step of the model, and the potential 
predictive baseline variable and a dummy variable representing condition were entered in 
the second step, with the interaction between these two variables entered in the third step.  
Sex, age, education level, race, psychiatric medication status, and number of comorbid 
diagnoses were not significantly associated with follow-up BDI scores when controlling 
for baseline depressive severity (all p values > .40).  Furthermore, these baseline 
variables did not significantly interact with condition to predict BDI outcomes.  In 
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addition, when entered alone or in interaction with condition, baseline RRS brooding and 
reflection scores, and RPI reward probability and environmental suppressor subscale 
scores were not significantly related to BDI score at follow-up (all p values > .13).   
Exploratory analyses: Does change in hypothesized mediators predict later change 
in depression severity? 
 Potential mechanisms of the overall BATD treatment effect could not be tested 
via statistical mediation due to a lack of no-treatment comparison group.  However, it 
may still be informative to examine changes in proposed mediators and their relationships 
to change in treatment outcome measures (Doss et al., 2006).  If a variable of interest 
does in fact mediate change in depressive severity, change in the proposed mediator early 
in treatment should be associated with change in depressive symptom severity later in 
treatment.  Furthermore, it would be expected that the inverse relationship (early change 
in depressive severity predicting later change in the proposed mediator) would be 
relatively weaker.  Therefore, change scores were calculated for RRS and RPI subscales 
between baseline and Week 3 (referred to as pre-to-mid RRS and RPI) and were 
examined as predictors of BDI change scores from Week 3 to 5 (mid-to-post BDI).  Next, 
the reverse analyses were conducted, regressing mid-to-post RRS/RPI scores onto pre-to-
mid BDI scores.  
 Pre-to-mid RRS change scores were not significantly associated with mid-to-post 
BDI change scores (b = -.29, t (24) = -1.22, p = .23).  However, pre-to-mid BDI change 
scores were significantly associated with mid-to-post RRS change scores, such that a 
greater reduction in BDI from baseline to midpoint was associated with a greater 
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reduction in RRS total scores from midpoint to posttreatment (b = -.66, t (23) = -3.095, p 
= .005).  When examining the RRS subscales specifically, a smaller reduction in RRS 
brooding from baseline to midpoint was associated with an increased reduction in BDI 
score from midpoint to posttreatment (b = -1.78, t (24) = -2.58, p = .016).  However, a 
larger significant relationship existed between pre-to-mid BDI change scores and mid-to-
post RRS brooding change scores (b = -.22, t (24) = -3.63, p = .001), suggesting that 
change in BDI may drive the later change in brooding.  Pre-to-mid RRS reflection change 
scores were not associated with mid-to-post BDI change scores (b = .70, t (24) = .85, p = 
.40).  However, a greater reduction in BDI from baseline to midtreatment was associated 
with an increase in reflective rumination from midtreatment to posttreatment (b = -.14, t 
(23) = -2.39, p = .03). 
 A similar pattern of results was found for RPI environmental suppressors: change 
in this variable from baseline to midpoint did not predict mid-to-post BDI change scores   
(b = -.54, t (24) = -.98, p = .34); however, a greater reduction in BDI scores from baseline 
to midpoint did predict an increase in mid-to-post RPI-ES change scores (b = -.20, t (23) 
= -2.20, p = .038). The relationship between pre-to-mid RPI-RP change scores and mid-
to-post BDI change scores was non-significant (b = .01, t (24)  = .025, p = .98), as was 
the inverse relationship  (b = .05, t (23) = .66, p = .52).   
 Finally, homework adherence at midtreatment (computed as the average of the 
proportion that each assigned activity was completed) was not significantly related with 
mid-to-post BDI change scores (b = -.01, t (24) = -.098, p = .92).  Additionally, pre-to-
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mid BDI change scores were not significantly associated with homework adherence at 
posttreatment (b = .25, t (16) = .36, p = .73). 
Exploratory Analysis: Does baseline CCT performance predict change in depressive 
symptoms?  
 A recent study (Siegle et al., 2014) indicated that the benefit of CCT on 
ruminative symptoms is strongest for individuals who are more engaged in the task at 
baseline.  The pupillary measurement used by Siegle and colleagues (2014) as a marker 
of engagement was not available in this study; however, the median interstimulus interval 
time (ISI) from baseline CCT PASAT performance could serve as a measure of initial 
performance.  A lower ISI is indicative of stronger performance.  In correlational 
analyses, stronger baseline performance on the PASAT was predictive of improvement in 
depressive symptoms at the level of a medium effect (BDI change r = -.36, p =.25 ; 
MADRS change r = -.51 , p = .09), however, these analyses had a very small sample size 
(n = 12) and did not reach significance.  In contrast, stronger baseline PASAT 
performance was associated with less improvement in ruminative brooding (r = .32, p = 
.28).  In a more conservative analysis, hierarchical regression models were used to 
examine whether PASAT performance at baseline predicted follow-up symptom 
outcomes when covarying for baseline symptom level.  PASAT performance was non-
significant (all p values > .33), and added explanation of 6% variance in depressive 
symptom outcomes for both BDI and MADRS, and 2% variance in RRS brooding 
outcomes.   
NAP Task Results 
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 NAP task analyses were performed on the completer sample only.  Consistent 
with previous studies, participants showed high accuracy rates on the baseline NAP task  
(control-positive trials: 97%, control-negative trials: 97%, priming-negative trials: 96%, 
priming-positive trials: 95%).  A 2x2 ANOVA was used to examine accuracy rates as a 
function of condition (priming vs. control) and valence (positive vs. negative).  No 
significant main or interactive effects were found (valence: F (1, 88) = .59, p = .44, ηp2 = 
.01; condition: F (1, 88) = 2.16, p = .15, ηp2 = .024; valence X condition: F (1, 88) = .002, 
p = .97, ηp2 = .00).    
 Mean response times for each condition on the NAP task over time are displayed 
in Table 8.  At baseline, a 2x2 ANOVA showed that response times did not differ as a 
function of NAP condition (F (1, 88) = 1.30, p = .26, ηp2 = .02), valence (F (1, 88) = .024, 
p = .88, ηp2 = .00), or condition by valence (F (1, 88) = .106, p = .75, ηp2 = .01).  The lack 
of a slowed response in the negative priming trials may indicate a lack of negative 
priming and therefore a reduced inhibitory control for both negative and positive stimuli. 
 In order to examine the relationship between inhibitory control and depression-
related variables, NAP scores were calculated for each individual by subtracting response 
times in the control condition from the response times in the negative priming condition 
(for positive and negative valences separately).  A higher NAP score reflects a greater 
negative priming effect (and therefore, greater inhibitory control).  NAP scores over the 
course of treatment are presented in Table 8.  The NAP-negative score at baseline was 
not significantly correlated with age (r = -.18, p = .42), sex (r = .14, p = .51), education (r 
= -.24, p = .27), or baseline BDI (r = .06, p = .80), RRS (r = .27, p = .22), MADRS (r = 
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.20, p = .36), or BAI (r = -.02, p = .93) scores (n = 23 for all correlations).  When 
examining the RRS brooding and reflection subscales separately, NAP-negative scores 
showed a trend toward a significant correlation with RRS-reflection scores (r = .38, p = 
.07).  RRS brooding was not significantly related to negative priming scores (r = .27, p = 
.21).   
 Does inhibitory control strengthen as an effect of treatment? If inhibitory 
control of irrelevant information improved with treatment, response times should 
specifically increase in the negative priming conditions, and, based on previous research 
(Joormann et al., 2010), might occur specifically in response to negative stimuli.  
Therefore, response time as a function of valence and condition were examined at 
midtreatment, posttreatment, and follow-up.  Two-way ANOVAs at each of these time 
points demonstrated no significant effects for valence, condition, or valence X condition 
(all p-values > .16, all ηp2 < .026).  Therefore, the sample did not exhibit a negative 
priming effect at any single timepoint in the study.   
 Given that one proposed mechanism of CCT is that it may enhance cognitive 
control of negative emotions, I also examined whether treatment condition influenced 
change in NAP scores across treatment.  Repeated measures ANOVA of NAP 
performance at baseline, posttreatment, and follow-up showed no effect of time, 
condition, or their interaction on NAP negative scores (time: F (2, 36) = .74, p = .49, ηp2 
= .039; condition: F (1, 18) = .21, p = .65, ηp2 = .012; time X condition: F (2, 36) = 1.61, 
p = .21, ηp2 = .082).  When examining NAP positive scores, the main effects of time and 
condition were non-significant (time: F (2, 36) = .58, p = .56, ηp2 = .031; condition: F (1, 
	  	  
43 
18) = .087, p = .77, ηp2 = .005).  However, there was a significant interaction between 
time and condition (F (2, 36) = 3.92, p = .029, ηp2 = .179; see Figure 4).  As depicted in 
Figure 4, for those assigned to CCT, NAP positive scores decreased between baseline and 
posttreatment and increased again between posttreatment and follow-up.  For those 
assigned to PVT, NAP positive scores increased between baseline and posttreatment and 
then remained relatively consistent between posttreatment and follow-up. 
 Is change in inhibitory control associated with symptom change?  To reflect 
the magnitude of change in inhibitory control over time, NAP change scores (for negative 
and positive stimuli separately) were calculated by subtracting the priming scores at 
baseline from the priming scores at posttreatment.  A positive value for this variable 
indicates increased priming (i.e., improvement in inhibitory control) over time.  Bivariate 
correlations were then used to examine whether change in inhibitory control was 
associated with symptom change.  NAP change scores were not associated with BDI (r = 
.21, p = .37), MADRS (r = -.15, p = .52), RRS brooding (r = .12, p = .61), or RRS 
reflection (r = .10, p = .69) change scores.  
 To examine this question differently, I also investigated whether individuals who 
responded to treatment demonstrated greater improvement in inhibitory control.  
Individuals classified as treatment responders at follow-up did not differ significantly 
from non-responders in NAP change scores (NAP-negative: t (20) = .19, p = .58, d = .24; 
NAP-positive: t (20) = -.31, p = .76, d= .13).    
 Does baseline inhibitory control predict symptom change? In exploratory 
analyses, we investigated whether NAP performance at baseline was predictive of 
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treatment outcome or related characteristics alone or in interaction with treatment 
condition.  Symptom measures at follow-up (BDI, MADRS, RRS, RPI) were regressed 
onto baseline NAP negative scores, treatment condition, and their interaction term.  The 
baseline score for the symptom measure of interest was included as a covariate.  Results 
are displayed in Table 9.  NAP negative scores at baseline, when alone and in interaction 
with treatment condition, did not significantly predict BDI at follow-up.  However, there 
was a trend toward a significant interaction between treatment condition and NAP 
negative scores in predicting MADRS scores at follow-up (b = -.033, t (18) = -1.86, p = 
.08, R2 change = .088).   
 Examination of this interaction effect revealed that in the CCT group, baseline 
NAP negative scores were trending toward a significant negative association with 
MADRS scores at follow-up (b = -.024, t (9) = -2.19, p = .06, R2 change = .19) such that 
individuals with increased inhibitory control of negative emotional material at baseline 
demonstrated lower follow-up MADRS scores.  However, in the PVT group, NAP 
negative scores were unrelated to follow-up MADRS scores (b = .035, t (8) = .83, p = 
.43, R2 change = .04).  
Conversely, NAP negative scores at baseline were significantly associated with 
increased RRS brooding scores at follow-up when covarying baseline brooding (b = .01, t 
(19) = 2.28, p = .04), but did not significantly interact with treatment condition (p = .12) 
in this model. Finally, NAP negative scores at baseline, alone and in interaction with 
treatment condition, did not significantly predict RRS-Reflection scores at follow-up. (all 
p values > .18) 
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IST Results 
 IST analyses were performed on the completer sample only.  The means and 
standard deviations for IST trials by condition and switch type are presented in Table 10.  
As expected, across all conditions, participants responded more slowly to switch trials 
than to non-switch trials (all p values < .002).  A 2x2 ANOVA of reaction times by 
Condition (emotion, gender) and Switch Type (switch, no-switch) showed main effects of 
both condition and switch type (condition: F (1, 98) = 4.26, p = .042, ηp2 = .04; switch 
type: F (1, 98) = 18.70, p = .00, ηp2 = .16).  Specifically, participants responded more 
quickly to gender trials than to emotion trials, and to no-switch trials than to switch trials.  
However, the Condition by Switch type interaction was not significant (F (1, 98) = .044, 
p = .83, ηp2  = .00).  Additionally, there was no significant difference between gender 
switch cost and emotion switch cost at baseline (t (22) = 1.15, p = .26; see Table 10 for 
all values).  Emotion and gender switch costs were highly correlated (r = .61, p = .002).  
 I also examined the effect of emotional valence within the emotion condition.  A 
2x2 ANOVA on reaction times with Valence (angry, neutral) and Switch type (switch, no 
switch) showed a main effect of switch type (F (1, 96) = 9.31, p = .003, ηp2 = .088).  
Participants responded more slowly to switch trials (either an angry to a neutral face or a 
neutral to an angry face) than to non-switch trials.  There was no main effect of valence 
(F (1, 96) = .01, p = .92, ηp2 = .00), and the interaction between valence and switch type 
was non-significant (F (1, 96) = .00, p = .96, ηp2 = .00). 
Emotion switch cost at baseline was not significantly correlated with age (r = -
.27, p = .20), baseline BDI (r = -.06, p = .78), MADRS (r = -.14, p = .51), BAI (r = -.01, 
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p = .96), RRS total (r = .02, p = .92), RRS brooding (r = -.22, p = .29), or RRS reflection 
scores (r = .02, p = .92) (n = 24 for all correlations).   There was no significant difference 
in emotion switch cost between men and women (F (1, 22) = 1.03, p = .32), although 
Cohen’s d (d = .43) indicated a moderate effect size, with women demonstrating a larger 
emotion switch cost than men.  There were no significant differences in emotion switch 
cost by race (F (2, 21) = .55, p = .59, ηp2 = .05) or education level (F (3, 20) = .87, p = 
.47, ηp2 = .12).   
Does switching capacity strengthen as an effect of treatment? Given that CCT 
may differentially enhance attentional switching capacity compared to PVT, I examined 
whether treatment condition influenced change in switch cost scores over the course of 
treatment.  Repeated measures ANOVA of switch cost scores at baseline, posttreatment, 
and follow-up showed no significant effect of time, treatment condition, or their 
interaction on emotion switch cost (time: F (2, 30) = 2.26, p = .12, ηp2 = .13; condition: F 
(1, 15) = .06, p = .81, ηp2 = .00; time by condition: F (2, 30) = 1.52, p = .24, ηp2 = .092).  
When examining gender switch cost scores, there was a main effect of time (F (2, 32) = 
4.46, p = .02, ηp2 = .22), showing that gender switch costs lessened over time.  However, 
there was no main effect of condition (F (1, 16) = .38, p = .55, ηp2 = .02) or time by 
condition (F (2, 32) = .95, p = .40, ηp2 = .06).  Because a number of participants did not 
have complete IST data from all three time points, the sample size was limited in this 
analysis (for emotion switch costs, nCCT = 7, nPVT = 10; for gender switch costs, nCCT = 7, 
nPVT = 11).   
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 I also examined whether the main effects of Switch Type and/or Emotion 
Condition found at baseline remained present through posttreatment and follow up.  At 
posttreatment, a 2x2 ANOVA showed a main effect of switch type (F (1, 66) = 12.92, p = 
.00, ηp2 = .16) but no longer showed a main effect of emotion condition (F (1, 66) = 2.03, 
p = .16, ηp2 = .03).  The switch type by emotion interaction was not significant (F (1, 66) 
= .052, p = .83, ηp2 = .001).  At follow-up, main effects of both switching condition (F (1, 
76) = 19.31, p = .00, ηp2 = .20) and emotion condition (F (1, 76) = 4.98, p = .029, ηp2 = 
.063) were found, such that participants responded more quickly to non-switch trials 
compared to switch trials, and to gender trials compared to emotion trials.  The condition 
by switch interaction was not significant at follow-up (F (1, 76) = .10, p = .76, ηp2 = .00).  
Is change in switching capacity associated with symptom change? To reflect 
the magnitude of change in switch costs over time, switch cost change scores (for 
emotion and gender conditions separately) were calculated by subtracting the switch 
costs at posttreatment from the switch costs at baseline.  A positive value for this variable 
indicates a larger decrease in switch cost over time.  Bivariate correlations were then used 
to examine whether change in switch costs were associated with symptom change.  
Emotion switch cost change scores were not significantly associated with BDI (r = .23, p 
= .37), MADRS (r = .22, p = .40), or RRS reflection (r = -.38, p = .13) change scores.  
There was a trend toward a negative correlation between emotion switch cost change and 
RRS-brooding change from baseline to posttreatment (r = -.43, p = .086) 
 To examine this question differently, I also investigated whether individuals who 
responded to treatment demonstrated greater change in switch costs over time.  
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Individuals classified as treatment responders showed a greater average reduction in 
emotion and gender switch costs at follow-up, but these differences were not significant 
(emotion switch cost: t (18) = -.69, p = .50, d = .33; gender switch cost: t (18) = -1.18, p = 
.25, d= .56).  
 Does switching capacity at baseline predict later symptom change? In 
exploratory analyses, we investigated whether IST performance at baseline was 
predictive of treatment outcomes.  Symptom measure scores at follow-up were regressed 
onto baseline Emotion Switch Cost scores and Gender Switch Cost scores (separately) 
alone and in interaction with treatment condition.  The baseline score for the symptom 
measure of interest was included as a covariate in the model.  Results are displayed in 
Table 11.  Baseline emotion switch cost, treatment condition, and their interaction did not 
predict BDI, MADRS, RRS-brooding, or RRS-reflection scores at follow-up.  
Additionally, baseline sex switch cost, condition, and their interaction did not predict 
BDI, MADRS, RRS-Brooding, or RRS-Reflection scores at follow-up.   
DISCUSSION 
 The current study tested whether CCT, a neurocognitive intervention previously 
shown to reduce depression symptoms, enhanced the effects of BATD when compared to 
a control condition (PVT).  I hypothesized that individuals receiving BATD + CCT 
would demonstrate a significantly greater reduction in depressive symptoms than 
individuals who received BATD + PVT.  Results showed that both treatment groups 
demonstrated a significant decline in depression symptom severity, ruminative brooding 
and anxiety, as well as an improvement in environmental reward.  However, individuals 
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who received CCT did not differ significantly from the PVT group on any of these 
clinical outcome measures.  This finding poses a contrast to two studies in which 
adjunctive CCT was shown to be clinically beneficial.  In the first test of CCT (Siegle et 
al., 2007), the addition of six sessions of CCT to an intensive outpatient program for 
severely depressed patients led to significant clinical improvement compared to treatment 
as usual.  A more recent study showed that the addition of CCT to five sessions of tDCS 
for depression was associated with more sustained symptom reduction than tDCS alone 
(Segrave et al., 2013).   
 Considering secondary aims, I hypothesized that relative to the BATD + PVT 
condition, the BATD + CCT condition would be associated with greater improvement in 
processes—ruminative brooding and cognitive control—thought to be specifically 
sensitive to CCT.  Specifically, I hypothesized that switching performance (as measured 
by the IST task) would improve as indicated by increased response latency, and that 
inhibitory control of negative material (as measured by the NAP task) would improve as 
indicated by an increased priming effect toward negative stimuli.  Finally, I hypothesized 
that ruminative brooding would decrease in the BATD + CCT condition relative to the 
BATD + PVT condition.  Study results were not supportive of these hypotheses.  
Changes in brooding, switching performance, and inhibitory control of negative material 
did not differ significantly by treatment condition.  In addition, although the patterns of 
change in NAP positive scores did differ between treatment groups, this effect did not 
occur in the hypothesized direction and was found only for positive emotional stimuli.  
Specifically, for those assigned to CCT, inhibitory control of positive stimuli decreased 
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during the treatment period and increased during the follow-up period.  For those 
assigned to PVT, inhibitory control of positive stimuli increased during the treatment 
period and then remained relatively consistent during the follow-up period.     
 With regards to Aim Two, I also hypothesized that changes in ruminative 
brooding and cognitive control would mediate the relationship between treatment 
condition and treatment outcome and the relationship between treatment condition and 
homework adherence.  However, this mediation effect was not present as evidenced by 
the lack of relationship between treatment condition and the proposed mediators.  This 
finding diverges from the recent work of Siegle and colleagues (2014), who found that, 
compared with treatment as usual, adjunctive CCT led to unique reductions in ruminative 
brooding.   
 Several factors may account for the failure of CCT to augment BATD in the 
current study.  Although the total overall dose of CCT provided in the current study was 
consistent with previous studies (e.g., Calkins et al., 2013), the timing of CCT sessions 
differed.  I administered CCT sessions immediately before four weekly therapy sessions, 
a schedule that was consistent with the type of dosing that might feasibly be offered as an 
adjunct to outpatient care.  Previous studies have administered CCT sessions either 2-3 
times per week (Siegle et al., 2007, Calkins et al., 2013), or daily for 1-2 weeks (Segrave 
et al., 2013; Brunoni et al., 2014). Thus, one possible explanation for the failure of CCT 
in the current study may be that the spacing between sessions was not sufficient to 
influence depressive symptoms.  The current study indicates that CCT in a weekly format 
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does not add benefit to BATD.  Future studies could consider supplementing outpatient 
treatment with daily at-home CCT to investigate the influence of an increased dose.   
 In addition, the current study is the first to my knowledge to pair CCT with a BA 
treatment.  BA is a well-supported therapy that has demonstrated very strong effects, 
comparable to antidepressant medication and cognitive therapy (Dimidjian et al., 2006), 
when administered as a full-length treatment package (typically 12-20 sessions).  Clinical 
gains have been relatively attenuated when BA has been offered in brief formats, and 
because it does not contain a cognitive component, BA provided a suitable platform for 
CCT to supplement.  However, it is possible that even in a brief format, the effects of 
BATD were robust enough to overshadow the benefits of CCT.  Indeed, the active 
comparison condition in this study (BATD + PVT) yielded an average reduction of 13 
points on the BDI, with thirty-eight percent of the ITT sample meeting criteria for 
remission.  In contrast, in the study by Siegle and colleagues (2007) that provided initial 
support for CCT, participants within the active comparison condition (an intensive 
outpatient program) saw no change, or possibly even an increase in BDI score over time.   
In addition to the strong effects on depressive symptoms across both conditions, 
treatment was associated with reductions in ruminative brooding and IST gender switch 
costs.  Based on the theory underlying CCT, I had hypothesized that these cognitive 
variables would show more improvement over time in the CCT condition.  The fact that 
both treatment conditions led to changes in these proposed mediator variables suggests a 
possible shared mechanism in CCT and BA treatment.  The lack of mechanisms unique 
to CCT found here is in contrast to the work of Siegle and colleagues (2007), who found 
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that adjunctive CCT was associated with increased activation of frontal brain regions.  
However, in Siegle’s (2007) study, the treatment as usual group did not undergo parallel 
neuroimaging analyses. Therefore, it may be that the changes found in prefrontal 
activation represent a non-specific consequence of improvement from depression rather 
than a unique effect of CCT.  This explanation would be in line with several 
neuroimaging studies demonstrating enhanced frontal activation following successful 
treatment for depression using antidepressant medications  (Fales et al., 2009; Mayberg et 
al., 2000) and cognitive behavior therapy (Ritchey, Dolcos, Eddington, Strauman, & 
Cabeza, 2011). 
 Despite the lack of evidence of unique CCT treatment effect within this study, the 
possibility remains that CCT may be beneficial for a select group of patients with 
depression.  MDD is a heterogeneous disorder (Winokur, 1997), and CCT targets a very 
specific mechanism (executive control) proposed to play a role in the disorder.  It may be 
that individuals will benefit from CCT only to the extent that they demonstrate deficits in 
this area (Siegle et al., 2014).  It may also be the case that individuals must participate in 
CCT in a specific manner in order to receive benefit; as Siegle and colleagues (2014, p. 
456) suggest, “some critical expenditure of cognitive resources” may be necessary in 
order for CCT to act on the cognitive substrates that might lead to emotional change.  
This is supported by an expanded analysis of the data from the initial trial of CCT, in 
which Siegle and colleagues (2014) examine predictors of response to CCT.  With a new 
analysis strategy, Siegle et al. found that while nearly all participants (assigned to 
treatment as usual (TAU) or TAU + CCT) saw improvement in depression symptoms, the 
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CCT group demonstrated significantly fewer ruminative brooding symptoms. 
Importantly, the authors also found that higher scores on a pre-treatment physiological 
measure of task focus predicted reduction in brooding in the CCT group, but not in the 
TAU group.  Their finding indicates that CCT may be most valuable for individuals who 
were strongly engaged with the task at the initiation of treatment. 
 The current study did not contain a measure of task engagement similar to that 
used by Siegle and colleagues (2014).  CCT performance at baseline, perhaps the index 
most similar to “task engagement”, was moderately correlated with BDI and MADRS 
follow-up outcomes, a finding consistent with Siegle’s (2014) work.  However, baseline 
CCT performance did not add unique prediction of outcomes when covarying for 
baseline symptom levels, and the sample size of this analysis was small (n = 12).  
 I also examined whether CCT was differentially effective for individuals with 
reduced cognitive control of emotional material, as operationalized by performance on 
the IST and NAP tasks.  Performance on the IST (a measure of switching performance) 
did not significantly interact with treatment condition to predict outcome.  In the NAP 
task analyses, a trend was found toward an interaction between baseline inhibitory 
control of negative emotional stimuli (NAP negative scores) and treatment condition in 
the prediction of follow-up MADRS scores.  That is, in the CCT group, but not the PVT 
group, individuals with higher inhibitory control of negative stimuli at baseline 
demonstrated reduced MADRS scores at follow-up.  This finding is consistent with the 
hypothesis that CCT effects are moderated by the baseline availability of cognitive 
resources.  However, it should be interpreted with caution due to the small sample size (n 
	  	  
54 
= 23) and the lack of similar pattern of moderation when examining BDI or RRS scores 
as measures of treatment outcome.       
Although it is suggested that CCT may act on depression through improvements 
in cognitive control and rumination, the current study does not provide support for these 
proposed mechanisms of action.  When compared to BA plus a well-designed sham 
condition, BA+ CCT did not lead to significantly greater reductions in depression or 
rumination, or to improvements in cognitive control.  One possible interpretation of these 
results is that CCT’s effects may be due to placebo or expectancy effect.  The designs of 
previous studies largely have been unable to rule out this possibility because they have 
not compared CCT to a sham condition.  In one of the few studies to use a sham 
comparison condition rather than TAU or no-treatment comparison, Calkins et al. (2014) 
did find positive effect of CCT on depressive symptoms compared to PVT.  However, a 
later study (Moshier, Molokotos, Stein, & Otto, in press) with an identical design (3 
sessions of CCT over 2 weeks in a sample of participants with elevated BDI scores) 
showed no effect of CCT compared to PVT.  The only other study to examine CCT 
relative to a sham condition did so in adjunct to tDCS.  Segrave and colleagues (2014) 
found that CCT plus tDCS, when compared to sham CCT plus tDCS and CCT plus sham 
tDCS was associated with sustained reduction in depressive symptoms.  The results 
suggest that tDCS and CCT in combination are acting as more than placebo, but their 
combination does not allow us to understand the unique influence of CCT.   
Given this pattern of findings, future research needs to be designed to evaluate whether 
CCT works through its hypothesized mechanisms rather than through expectancy effect.  
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This will require the use of adequate comparison conditions that offer similar expectancy 
effects, such as sham computerized tasks.  Furthermore, we should continue to examine 
mediators of CCT effects, with a focus on identifying those that are unique to CCT 
compared to active treatments or placebos.  This has been a challenge across 
psychosocial and pharmacological treatments for depression, with some arguing that a 
substantial proportion of the effects of treatment may be due to placebo effect and/or 
natural changes in course of depression (Kirsch & Sapirstein, 1998).  Consistent with 
this, rates of response to pill placebo for depression have been shown to average 30% 
(Walsh, Seidman, Sysko, & Gould, 2002).  Neuroimaging studies may be one way to 
distinguish the theorized effects of treatment from placebo effects.  Studies have 
identified changes in brain regions unique to specific treatments, such as fluoxetine or 
CBT, and not seen in placebo (see Benedetti, Mayberg, Wager, Stohler, & Zubieta, 
2005).  However, one potential problem for research on the neural mechanisms of CCT is 
that the placebo effect in depression has been shown to be associated with increases in 
DLPFC activation, the very area which CCT targets.  Thus, the brain regions that might 
change if CCT works the way it has been hypothesized to might also be expected to 
change in response to placebo, making it difficult to distinguish between the two. 
Brief Behavioral Activation Therapy for Depression 
 The present study, although focused on the clinical efficacy of adjunctive CCT, 
also provides support for the further study and use of BATD for individuals with MDD.  
Following four sessions of BATD, patients demonstrated an average 11-point reduction 
in BDI score and 8-point reduction in MADRS score.  Thirty-five percent of the sample 
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reached remission status by the follow-up visit.  These results are consistent with a 
growing body of evidence supporting the use of brief BA treatments.  The majority of 
these studies have examined time-limited BA protocols in individuals with elevated, but  
not necessarily clinical levels of depression (e.g., Magidson et al., 2011; Daughters et al., 
2008, Gawrasiak & Hopko, 2009).  Our results expand upon this work to show that brief 
treatment may be useful for those with a clinical-level diagnosis of MDD.  They replicate 
the results of an open trial conducted by Gross and Haren (2011) which demonstrated that 
four sessions of BA in a primary-care setting significantly reduced MDD symptoms in 
veterans.  An important next step will be to compare time-limited BATD to a control 
condition within a sample of clinically depressed patients.     
 The expanding support for brief BA treatments has important implications for 
depression treatment efforts.  Estimates suggest that nearly 40% of patients who 
experience a major depressive episode choose not to seek treatment, and that cost is often 
a major factor in this decision (Mojtabai, 2009).  Furthermore, fewer than half of 
individuals who do seek treatment for depression receive adequate care (Chermack et al., 
2008; Prins et al., 2010; Witt et al., 2011).  BA has potential to help alleviate the large 
unmet need for affordable, accessible, evidence-based treatment for depression.  
Research has shown that non-specialists can be trained to effectively administer BA 
(Ekers et al., 2011), which would allow for an increased number of available clinicians as 
well as a lower cost of intervention.  BA can also be flexibly adapted for different 
settings and populations; for instance, programs have been modified to focus on smoking 
cessation, substance use disorders, and HIV medication adherence in the context of 
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depressive symptoms (Magidson et al., 2011; Daughters et al, 2008; Macpherson et al., 
2010).  Finally, the format of BA also lends itself to be used in low-cost and transportable 
modes of intervention, such as bibliotherapy and Internet-based treatment.  Recent 
studies have provided initial support for the effectiveness of these delivery methods 
(O’Mahen et al., 2013; Carlbring et al., 2013).   
 Given its brevity, BA may be an important intervention in a stepped-care 
approach which offers different levels of interventions.  From this perspective, it would 
be particularly useful to understand which patients with MDD are likely to benefit from 
brief BA treatment and which patients need more resource-intensive treatment.  The 
current study did not clarify this question, finding that baseline clinical measures 
(rumination, environmental reward) and characteristics such as sex, age, education level, 
race, psychiatric medication status, and psychiatric comorbidity were not significantly 
associated with treatment outcome after controlling for baseline severity of depressive 
symptoms.  This may reflect a problem seen across the literature - that variables that have 
been shown to predict outcome or course of illness alone, such as cognitive style, lose 
significance when considered in addition to baseline depression symptoms (Otto et al., 
2007).  Continued research with larger samples is needed so that we may begin to 
identify predictors of treatment outcome that will allow for more tailored treatment 
recommendations. 
 The current study also examined potential mechanisms of BATD effects, with 
focus on changes in ruminative brooding, environmental reward, and adherence to 
scheduled activities. Because of the lack of comparison group in the current study, formal 
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mediation analyses of BATD effects were not possible.  Instead, I examined mid-
treatment changes in proposed mediators of BATD (brooding, environmental reward, and 
homework adherence) and their relationships to subsequent change in depressive 
symptoms.  If these variables were mediators of outcome, one would expect that early 
changes in these variables would predict later changes in depression symptom severity.  
However, the opposite pattern was found: early changes in depressive symptoms (as 
measured by the BDI) were more strongly related with later changes in rumination and 
environmental reward.  In addition, the relationship between homework adherence and 
later change in BDI was non-significant.  The lack of mediation could indicate that BA 
exerts change in depression through other mechanisms, such as cognitive change.  
Alternatively, it may be that the measures used, such as the RPI and homework adherence 
ratings, do not accurately capture changes in activity level or positive reinforcement 
(theorized mechanisms of BA).  For instance, although homework adherence ratings 
assign equal weight to every activity that a patient completes, it is likely that each 
assigned activity in BA is differentially reinforcing for a patient.  Furthermore, such 
ratings of activity completion may not capture other ways that patients initiate BA 
strategies in their daily lives.  Future research on the mechanisms of change in BA might 
benefit from more precise measurement strategies such as daily activity diaries or 
ecological momentary analysis. 
Cognitive Control 
 In the current study, I examined two measures of cognitive control of emotional 
material as potential mediators of CCT treatment effects.  Both measures, the Negative 
	  	  
59 
Affective Priming (NAP) Task and the Internal Shift Task (IST), have been linked with 
rumination and depressive symptoms in previous work.  As noted above, adjunctive CCT 
was generally not associated with differential clinical change between groups.  However, 
exploration of data from these tasks across the treatment groups has potential to inform 
research into cognitive control processes in patients with depression more generally. 
Inhibitory control – NAP task.  Previous research on the NAP task has 
compared clinical and non-clinical samples, showing that patients with MDD 
demonstrate reduced inhibitory control of negative but not positive emotional 
information, while healthy controls show priming effects (indicating inhibitory control) 
to both negative and positive information (Joormann & Gotlib, 2010).  This difference 
could not be replicated in the current study because there was no healthy comparison 
group.  However, within-subject tests of baseline NAP performance revealed no 
significant main effects of priming condition or valence of stimuli.  Thus, in contrast to 
previous studies, participants in the current study did not demonstrate a priming effect for 
negative or positive stimuli.  These results may indicate reduced cognitive control in 
response to emotional content more globally (as opposed to only negative stimuli).  
Although it is unclear why these results differ from Joormann & Gotlib in this way, they 
are consistent the work of De Lissnyder and colleagues (2012), who found that although 
dysphoric individuals demonstrated deficits specific to negative emotional content, 
clinically depressed individuals demonstrated a broader, more global cognitive 
impairment in set-shifting ability.  One possibility is that in more severely depressed 
individuals, exposure to negative emotional stimuli has a more sustained influence on 
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inhibitory control; thus they may be less likely to be influenced by the valence of the 
stimuli appearing on a trial-by-trial basis on these types of experimental tasks (De 
Lissnyder et al., 2012).  
 In order to better understand the clinical relevance of inhibitory control processes, 
I examined the relationships between clinical characteristics and NAP task performance 
at baseline, and also analyzed changes in NAP task performance over the course of 
treatment.  Consistent with previous work in a sample including healthy controls and both 
currently and formerly depressed individuals (Joormann & Gotlib, 2010), I found a trend-
level positive association, reflecting a medium effect size (r = .38), between inhibitory 
control of negative information (NAP negative scores) and baseline scores on the 
reflection subscale of the RRS.  However, in the current study, correlations between 
baseline NAP performance and all other clinical measures were small in size and non-
significant.  This diverges with the results of Joormann and Gotlib (2010), who found that 
in depressed patients, increased levels of brooding were strongly (r = -.41) related to 
reduced inhibitory control of negative information.  
 Joormann and Gotlib (2010) also found that unlike depressed patients, formerly 
depressed individuals did not demonstrate a reduced inhibitory control of negative 
information.  Interestingly, they found that these remitted depressed individuals showed a 
failure to inhibit positive information, possibly demonstrating a positive attentional bias.  
This would suggest that with successful treatment, depressed patients might gain 
inhibitory control for negative material and begin to show a bias toward positive 
information.  In the current study, I found no evidence of change in inhibitory control of 
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negative information across the course of treatment.  However, participants who received 
CCT showed a reduction in NAP positive scores between baseline and posttreatment, and 
a subsequent increase during the follow-up period.  Although this pattern may be a sign 
that CCT leads to a positive attentional bias (at least acutely), this result must be 
interpreted with caution, as the change in NAP positive score was not associated with any 
measure of clinical outcome.  Furthermore, the decrease in NAP positive scores reflects a 
reduction in inhibitory control of positive information, which is at odds with the 
hypothesis that CCT would increase inhibitory control. 
 More research is needed to understand how the NAP task relates to clinical 
processes and to assess changes in NAP performance in response to treatment.  It may be 
that individuals in the current study did not improve enough clinically to see a change in 
inhibitory control as was apparent in the sample of formerly depressed patients 
(Joormann & Gotlib, 2010).  It is also possible that changes in inhibitory control may 
follow symptom change, and that eight weeks was too short of a period in which to detect 
this change.   
 In exploratory analyses, I also examined whether baseline inhibitory control of 
negative material predicted treatment outcomes alone or in interaction with treatment 
condition.  Findings showed that although baseline inhibitory control of negative material 
was unrelated to depression symptom severity at follow-up, it did significantly predict 
higher brooding scores at follow-up.  There was no significant treatment condition by 
NAP score interaction, suggesting that this effect reflected changes related to BA 
treatment rather than CCT.  These results suggest that BA may be more likely to act on 
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depressive brooding in individuals with lower levels of pre-treatment inhibitory control 
of negative emotional material.  Given that brooding has been uniquely associated with 
negative outcomes such as suicide ideation (Miranda & Nolen-Hoeksema, 2007) and 
relapse following depression treatment (Michalak, Holz, & Teismann, 2011), there is 
clinical value in reducing depressive brooding in addition to depression symptoms.  In the 
future, it may be worth examining whether inhibitory control moderates reduction in 
brooding across other types of treatments in addition to BA.  It may also be important to 
understand why individuals with higher inhibitory control of negative material may not 
experience reduction in brooding through BA treatment and how BA could be modified 
in order to do so.  However, further replication of this finding is needed given the 
exploratory nature of the analysis and the limited sample size.  
 In sum, the current examination of NAP task performance at baseline and over the 
course of treatment found that depressed participants failed to inhibit both positive and 
negative emotional information and suggested that inhibition of negative material did not 
change over the course of treatment.  Furthermore, NAP task performance was not 
significantly associated with baseline brooding (r = .27).  This finding is inconsistent 
with the only previous study to examine NAP task performance in a clinically depressed 
sample, which found a moderate and negative correlation between NAP negative scores 
and brooding (r  = -.41; Joormann et al., 2010).  Because both of these studies have been 
limited by small sample sizes, more work is needed in larger samples to determine the 
clinical relevance of inhibitory control within depressed populations.  Understanding how 
variables other than clinical severity of depression and rumination might relate to 
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inhibitory control may help to advance the research in this area.  For instance, 
Joormann’s study found evidence that improved inhibitory control was associated with 
the use of adaptive emotion regulation strategies such as reappraisal (Joormann & Gotlib, 
2010).  Future work might continue along this line by examining how inhibitory control 
relates to other processes involved in depression such as reward sensitivity or 
autobiographical memory.  Moreover, little is known about whether the NAP task is 
sensitive to factors such as current affective state, working memory load, fatigue, or 
effort.  Experimental studies which measure or manipulate these factors may lead to a 
more comprehensive understanding of the NAP task and the role of inhibitory control in 
depression. 
Switching performance – IST task.  I also assessed cognitive control with the 
Internal Shift Task (IST), which assesses the ability to switch attention between items in 
working memory in response to images of faces.  The IST allows for assessment of 
response time performance when emotional expression is task-relevant (the emotion 
condition) or not task relevant (gender condition), and under conditions of switch trials 
(the trial stimuli presented is of a different category than that of the previous trial) or no-
switch trials (the trial presents stimuli within the same category as the previous trial).   
 At baseline, participants demonstrated a slower response to switch trials 
(compared to non-switch trials) and a slower response to trials in which emotional 
expression was task-relevant (compared to trials where gender was the task-relevant 
feature).  The slowed response to switch trials across both gender and emotion conditions 
is consistent with findings by De Lissnyder et al. (2012), who found that clinically-
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depressed individuals demonstrated a general switching impairment.  That is, unlike 
dysphoric individuals, who demonstrated a switching impairment specifically in the 
emotion condition, depressed individuals demonstrated a switching impairment in both 
conditions.  Although the lack of control group in the current study prevents from making 
the conclusion that switching performance was impaired relative to healthy individuals, 
the results are broadly consistent with this previous work.  
 De Lissnyder and colleagues (2012) also found that IST switch costs (the average 
difference between response times to switch and non-switch trials) were positively 
correlated with rumination and depression symptoms in depressed individuals.  However, 
in the current study I found no significant relationship between baseline IST performance 
and clinical measures.  In addition, baseline switch costs did not predict treatment 
outcome when controlling for baseline levels of symptom severity.      
 In exploratory analyses, I also examined change in switch costs as a function of 
time, treatment condition, and their interaction. Results indicated that over time, 
participants demonstrated increased ability to switch attention in the gender condition of 
the IST; however, no change occurred in performance on the emotion condition.  This is 
the second study to demonstrate enhanced performance on the gender condition of the 
IST over the course of time (Onraedt & Koster, 2014).  This improvement may simply be 
a practice effect from repeated exposure to the IST task.  However, the current data 
suggest that it is more than this.  Compared to non-responders, treatment responders 
demonstrated a trend toward a greater reduction in gender switch cost over time.  Thus, 
change in IST performance in depressed individuals may be related to clinical gains over 
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the course of treatment.  If this finding can be replicated in larger samples of patients 
receiving treatment for depression, it will then be important to investigate whether 
change in switching performance is a mechanism or consequence of clinical symptom 
change.       
Limitations 
 Findings of this study must be interpreted in the context of a number of 
limitations.  Because both treatment groups received BATD and there was not a no-
treatment comparison condition, I cannot confirm that the reduction in depressive 
symptoms was due to BATD rather than another unknown cause.  Second, the small 
sample size may have prevented detection of predictors or mediators of treatment 
response.  Baseline clinical and demographic measures did not significantly predict 
treatment outcome and effect sizes were small.  The most promising predictor of outcome 
was baseline performance on the PASAT task, with stronger performance predicting 
greater improvement in BDI and MADRS scores at the level of a medium but non-
significant effect.  However, sample size was very limited for this analysis, and was also 
limited for detecting changes over time in the cognitive control tasks as a function of 
treatment condition. Additionally, the study does not allow conclusions to be made 
regarding the effects of CCT or BATD past the one-month follow-up period.  The sample 
was predominantly White and highly educated, with more than half the sample having 
obtained a Bachelor’s degree or higher.  Therefore, caution should be taken in 
generalizing these results to non-White or less educated patient groups.  Finally, although 
participant report suggests that drop-out did not occur due to unacceptability of CCT, a 
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significantly greater number of participants in the CCT condition dropped out of the 
study compared to the PVT condition.  Future research should address these limitations 
using larger, more diverse samples, collecting information about CCT acceptability, and 
by increasing the length of the follow-up period following treatment.  
CONCLUSION 
 The current project represents an assessment of a mechanism-focused, low-cost 
augmentation strategy for the treatment of depression.  Weekly CCT was not found to 
add clinical benefit to a four-session BATD treatment, and CCT augmentation was not 
associated with relative increases in cognitive control, ruminative brooding, or homework 
adherence.  These results suggest that the effects of CCT may not be as robust as 
previous studies have suggested.  This is consistent with a recent re-analysis of the most 
comprehensive CCT study in clinically depressed patients (Siegle et al., 2014) suggesting 
that CCT may only benefit those who are able to allocate sufficient attentional resources 
toward the task.  Despite the failure of CCT to aid BATD when administered in weekly 
format, there is continued need to investigate CCT.  Future work should prioritize 
understanding for whom CCT may be effective and the conditions that optimize its 
effectiveness.   
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TABLES 	  
Table 1.  Study measures and procedures by visit.  
 
 
Screening 
(Week 0) 
Baseline 
(Week 1) Week 2 Week 3 Week 4 
Endpoint 
(Week 5) 
Follow-
up 
(Week 8) 
Informed 
consent X       
SCID-IV X       
Personal 
Data form X       
BDI  X X X X X X 
MADRS  X    X X 
BAI  X    X X 
RPI  X  X  X X 
RRS  X  X  X X 
NAP task  X  X  X X 
IST task  X  X  X X 
Homework 
adherence   X X X X  
CCT or 
PVT  X X X X   
BATD 
session  X X X X  
 
 
Note. SCID-IV = Structured Clinical Interview for DSM-IV; BDI = Beck Depression Inventory-
II, MADRS = Montgomery-Asberg Depression Rating Scale; BAI = Beck Anxiety Inventory; 
RPI = Reward Probability Index; RRS = Ruminative Response Scale; NAP task = Negative 
Affective Priming Task; IST = Internal Shift Task; CCT = Cognitive Control Training; PVT = 
Peripheral Vision Training; BATD = Brief Behavioral Activation Therapy for Depression 
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Table 2.  Participant characteristics of the Intent-to-Treat sample. 
 All participants  
(N = 34) 
CCT Group  
(n = 21) 
PVT Group  
(n = 13) 
Sex, % female (n) 52 (18) 47.6 (10) 61.5 (8) 
Age, Mean (SD) 35.6 (14.6) 36.3 (14.4) 34.38 (15.4) 
Race    
   Caucasian, % (n) 73.5 (25) 85.7 (18) 53.8 (7) 
   African American,  
   % (n) 20.6 (7) 9.5 (2) 38.5 (5) 
   Asian, % (n) 0 (0) 0 (0) 0 (0) 
   American Indian or     
   Alaskan Native % (n) 0 (0) 0 (0) 0 (0) 
   Native Hawaiian or  
   Pacific Islander % (n) 0 (0) 0 (0) 0 (0) 
   Other % (n) 5.9 (2) 4.8 (1) 7.7 (1) 
Ethnicity     
   Hispanic % (n) 5.9 (2) 4.8 (1) 7.7 (1) 
   Non-Hispanic % (n) 94.1 (32) 95.2 (20) 92.3 (12) 
Education    
   No degree 2.9 (1) 4.8  (1) 0 (0) 
   High School degree 11.8 (4) 9.5 (2) 15.4 (2) 
   Some college 29.4 (10) 19.0 (4) 46.2 (6) 
   Bachelor’s degree 26.5 (9) 28.6 (6) 23.1 (3) 
   Graduate training 29.4 (10) 38.1 (8) 15.4 (2) 
Taking psychiatric 
medication, % (n) 29.4 (10) 28.6 (6) 30.8 (4) 
BDI, Mean (SD) 29.6 (10.1) 28.8 (9.6) 30.8 (11.0) 
MADRS, Mean (SD) 26.6 (7.6) 26.9 (8.2) 26.2 (6.9) 
RRS, Mean (SD) 59.5 (9.9) 59.1 (7.6) 57.6 (13.2) 
RPI, Mean (SD) 43.3 (7.4) 43.1 (6.9) 43.8 (8.4) 
 
Note. BDI = Beck Depression Inventory-II, MADRS = Montgomery-Asberg Depression  
Rating Scale; RRS = Ruminative Response Scale; RPI = Reward Probability Index 
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Table 3.  Participant characteristics of the completer sample. 
 All Study 
Completers  
(n = 26) 
CCT Group 
Completers 
(n = 14) 
PVT Group 
Completers 
(n = 12) 
Sex, % female (n) 61.5 (16) 64.3 (9) 58.3 (7) 
Age, Mean (SD) 35.5 (14.7) 37.2 (14.0) 33.6 (15.8) 
Race    
   Caucasian, % (n) 73.1 (19) 85.7 (12) 58.3 (7) 
   African American,  
   % (n) 19.2 (5) 7.1 (1) 33.3 (4) 
   Asian, % (n) 0 (0) 0 (0) 0 (0) 
   American Indian or     
   Alaskan Native % (n) 0 (0) 0 (0) 0 (0) 
   Native Hawaiian or  
   Pacific Islander % (n) 0 (0) 0 (0) 0 (0) 
   Other % (n) 7.7 (2) 7.1 (1) 8.3 (1) 
Ethnicity     
   Hispanic % (n) 7.7 (2) 7.1 (1) 8.3 (1) 
   Non-Hispanic % (n) 92.3 (24) 92.9 (13) 91.7 (11) 
Education    
   No degree 0 (0) 0 (0) 0 (0) 
   High School degree 11.5 (3) 7.1 (1) 16.7 (2) 
   Some college 30.8 (8) 21.4 (3) 41.7 (5) 
   Bachelor’s degree 30.8 (8) 35.7 (5) 25.0 (3) 
   Graduate training 26.9 (7) 35.7 (5) 16.7 (2) 
Taking psychiatric 
medication, % (n) 34.6 (9) 35.7 (5) 33.3 (4) 
BDI, Mean (SD) 29.4 (9.1) 27.8 (6.6) 31.3 (11.3) 
MADRS, Mean (SD) 26.2 (6.4) 25.6 (6.3) 27.0 (6.6) 
RRS, Mean (SD) 58.9 (10.7) 59.3 (8.2) 58.5 (13.4) 
RPI, Mean (SD) 44.1  (6.9) 44.7 (5.3) 43.3 (8.6) 
Note. BDI = Beck Depression Inventory-II, MADRS = Montgomery-Asberg  
Depression Rating Scale; RRS = Ruminative Response Scale;  
RPI = Reward Probability Index  
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Table 4.  Participant characteristics by completer and dropout status. 
 Completers  
(n = 26) 
Dropouts  
(n = 8) 
Sex, % female (n) 61.5 (16) 25.0 (2) 
Age, Mean (SD) 35.5 (14.7) 35.6 (15.2) 
Race   
   Caucasian, % (n) 73.1 (19) 75.0 (6) 
   African American,  
   % (n) 19.3 (5) 25.0 (2) 
   Asian, % (n) 0 (0) 0 (0) 
   American Indian or     
   Alaskan Native % (n) 0 (0) 0 (0) 
   Native Hawaiian or  
   Pacific Islander % (n) 0 (0) 0 (0) 
   Other % (n) 0 (0) 0 (0) 
Ethnicity    
   Hispanic % (n) 7.6 (2) 0 (0) 
   Non-Hispanic % (n) 92.3 (24)  100.0 (8) 
Education   
   No degree 0 12.5 (1) 
   High School degree 11.5 (3) 12.5 (1) 
   Some college 30.8 (8) 25 (2) 
   Bachelor’s degree 30.8 (8) 12.5 (1) 
   Graduate training 26.9 (7) 37.5 (3) 
Taking psychiatric 
medication, % (n) 34.6 (9) 12.5 (1) 
BDI, Mean (SD) 29.4 (9.1) 30.0 (13.5) 
MADRS, Mean (SD) 26.2 (6.4) 27.9 (11.2) 
RRS, Mean (SD) 58.9 (10.7) 57.1 (7.4) 
RPI, Mean (SD) 44.1 (6.9) 40.9 (8.8) 
Treatment Condition   
   CCT, % (n) 53.8 (14) 87.5 (7) 
   PVT, % (n) 46.2 (12) 12.5 (1) 
Note. BDI = Beck Depression Inventory-II, MADRS = Montgomery-Asberg Depression  
Rating Scale; RRS = Ruminative Response Scale; RPI = Reward Probability Index;  
CCT = Cognitive Control Training; PVT = Peripheral Vision Training  
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Table 5. Primary and secondary outcome measures for all randomized participants at 
baseline, mid-treatment, post-treatment, and follow-up (N = 34). 
 Baseline Mid-treatment Post-treatment Follow-up 
BDI     
PVT 30.7 (11.0) 24.0 (12.5) 18.6 (13.3) 18.2 (14.6) 
CCT 28.8 (9.6) 23.9 (11.3) 23.1 (10.8) 22.0 (11.8) 
MADRS     
PVT 26.2 (6.9) -- 17.00 (9.9) 17.5 (11.7) 
CCT 26.9 (8.2) -- 19.76 (11.1) 20.0 (9.8) 
RRS total     
PVT 57.6 (13.2) 56.2 (16.2) 48.9 (15.2) 44.7 (14.3) 
CCT 59.1 (7.6) 57.2 (8.7) 54.6 (12.2) 52.0 (11.2) 
RRS-Brooding     
PVT 13.2 (3.4) 13.1 (4.2) 11.7 (3.7) 10.2 (3.9) 
CCT 12.9 (2.4) 12.1 (2.7) 12.1 (3.7) 11.7 (3.2) 
RPI-RP     
PVT 23.7 (5.4) 24.2 (6.6) 27.0 (6.4) 27.9 (7.2) 
CCT 22.9 (5.0) 22.9 (5.8) 26.2 (6.7) 25.1 (6.7) 
RPI-ES     
PVT 20.1 (4.6) 21.2 (5.8) 23.2 (5.5) 23.5 (5.4) 
CCT 20.2 (4.4) 19.2 (4.5) 20.5 (5.7) 21.0 (5.1) 
BAI     
PVT 17.8 (9.4) -- 11.6 (7.4) 13.2 (11.4) 
CCT 15.8 (8.5) -- 13.7 (8.9) 12.8 (9.3) 
Note. CCT = Cognitive Control Training; PVT = Peripheral Vision Training; BDI = Beck 
Depression Inventory-II, MADRS = Montgomery-Asberg Depression Rating Scale; RRS total = 
Ruminative Response Scale total; RRS-Brooding = Brooding subscale of Ruminative Response 
Scale; RPI-RP = Reward Probability Index – Reward Probability subscale; RPI-ES = Reward 
Probability Index – Environmental Suppressors subscale; BAI = Beck Anxiety Inventory 
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Table 6.   Primary and secondary outcome measures for all treatment completers at 
baseline, mid-treatment, post-treatment, and follow-up (n = 26). 
 
 Baseline Mid-treatment Post-treatment Follow-up 
BDI     
PVT 31.3 (11.3) 23.9 (13.0) 18.1 (13.7) 17.6 (15.1) 
CCT 27.8 (6.9) 22.1 (9.0) 20.9 (7.5) 19.2 (9.1) 
MADRS     
PVT 27.0 (6.6) -- 17.0 (10.4) 17.6 (12.3) 
CCT 25.5 (6.6) -- 17.8 (9.0) 18.2 (6.3) 
RRS total     
PVT 58.5 (13.4) 56.9 (16.7) 49.0 (15.9) 44.5 (14.9) 
CCT 59.8 (8.6) 57.3 (10.3) 53.3 (14.1) 49.1 (11.3) 
RRS-Brooding     
PVT 13.5 (3.3) 13.4 (4.2) 11.9 (3.9) 10.3 (4.1) 
CCT 13.1 (2.5) 11.9 (2.9) 12.1 (4.1) 11.4 (3.2) 
RPI-RP     
PVT 23.4 (5.5) 23.9 (6.8) 27.0 (6.7) 27.9 (8.1) 
CCT 23.8 (3.6) 23.6 (5.4) 28.4 (6.6) 26.3 (7.0) 
RPI-ES     
PVT 19.9 (4.8) 21.1 (6.0) 23.3 (5.7) 23.7 (5.6) 
CCT 20.9 (3.3) 19.1 (3.7) 20.8 (5.7) 21.6 (4.4) 
BAI     
PVT 18.3 (9.6) -- 11.6 (7.8) 13.3 (11.9) 
CCT 15.6 (8.7) -- 12.7 (8.5) 11.2 (9.0) 
Note. CCT = Cognitive Control Training; PVT = Peripheral Vision Training; BDI = Beck Depression 
Inventory-II, MADRS = Montgomery-Asberg Depression Rating Scale; RRS total = Ruminative  
Response Scale total; RRS-Brooding = Brooding subscale of Ruminative Response Scale;  
RPI-RP = Reward Probability Index – Reward Probability subscale; RPI-ES = Reward  
Probability Index – Environmental Suppressors subscale;  BAI = Beck Anxiety Inventory  
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Table 7.  Response and remission rates by treatment condition. 
 
 Intent-to-treat Sample Completer Sample 
 CCT PVT Chi- Square CCT PVT 
Chi- 
Square 
Week 5       
% responders (n) 14.3 (3) 38.5 (5) 2.61 21.4 (3) 41.7 (5) 1.24 
% remitters (n) 9.5 (2) 30.8 (4) 2.49 14.3 (2) 33.3 (4) 1.32 
Week 8       
% responders (n) 23.8 (5) 38.5 (5) 0.83 30.8 (4) 41.7 (5) 0.32 
% remitters (n) 19.0 (4) 38.5 (5) 1.56 30.8 (4) 41.7 (5) 0.32 
Note. CCT = Cognitive Control Training; PVT = Peripheral Vision Training 
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Table 8.  Means and Standard Deviations (SDs) for NAP task response times and NAP 
scores over time. 
 
Week 1 
Week 3 
(mid-
treatment) 
Week 5  
(post-
treatment) 
Week 8 
(follow-up) 
Control – 
negative RT 
874.21 
(110.88) 
841.50 
(109.55) 
824.41 
(137.58) 
799.27 
(106.34) 
Control  - 
positive RT 
878.48 
(105.18) 
816.82 
(90.87) 
798.91 
(90.98) 
796.26 
(118.36) 
NP – negative RT 911.26 (144.72) 
868.81 
(108.70) 
837.28 
(143.55) 
818.30 
(101.80) 
NP – positive RT 899.10 (120.92) 
856.42 
(112.13) 
813.99 
(102.81) 
828.34 
(106.82) 
NAP score  - 
negative 
37.05  
(98.88) 
27.31 
(72.82) 
12.87 
(77.74) 
19.03 
(65.24) 
NAP score - 
positive 
20.61 
(74.22) 
39.60 
(69.10) 
15.08 
(63.01) 
32.08 
(55.90) 
 
Note.  
Control negative RT = Response time (in ms) for control trials with negative stimuli as target 
Control – positive RT =Response time (in ms) for control trials with positive stimuli as target 
NP- negative RT = Response time (in ms) for negative priming trials with negative stimuli as 
target 
NP - positive RT = Response time (in ms) for negative priming trials with positive stimuli as 
target 
NAP score - negative = difference between mean RT for Control-negative and Negative priming- 
negative trials (higher score represents greater inhibitory control of negative stimuli) 
NAP score  - positive: difference between mean RT for Control-positive and Negative priming- 
positive trials (higher score represents greater inhibitory control of positive stimuli) 
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Table 9.  Hierarchical multiple regression analyses of the predictive influence of baseline 
NAP-negative scores and treatment condition on treatment outcomes at follow-up. 
 B t p Model R2  
BDI week 8     
Step 1    .32 
     BDI week 1 .73 3.11* .01  
Step 2    .33 
     NAP-negative score week 1 -.01 -.06 .76  
     Treatment Condition 1.49 .64 .53  
Step 3    .38 
     NAP-negative X Condition -.03 -1.18 .26  
     MADRS week 8     
Step 1    .43 
     MADRS week 1 .96 4.01** .00  
Step 2    .45 
     NAP-negative score week 1 -.01 -.56 .58  
     Treatment Condition 1.15 .69 .50  
Step 3    .54 
     NAP-negative X Condition -.03 -1.86 .08  
     
RRS-brooding week 8     
Step 1    .33 
     RRS total week 1 .78 3.23* .00  
Step 2    .49 
     NAP-negative score week 1 .01 2.28* .04  
     Treatment Condition .26 .44 .67  
Step 3    .55 
     NAP-negative X Condition -.01 -1.64 .12  
     
RRS-reflection week 8     
Step 1    .52 
     RRS total week 1 .64 4.74** .00  
Step 2    .55 
     NAP-negative score week 1 .01 1.11 .28  
     Treatment Condition .22 .44 .67  
Step 3    .57 
     NAP-negative X Condition -.01 -.86 .40  
Note.  BDI = Beck Depression Inventory-II; NAP = Negative Affective Priming task; MADRS = 
Montgomery-Asberg Depression Rating Scale; RRS-brooding = Brooding subscale of the 
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Ruminative Response Scale; RRS-reflection = Reflection subscale of the Ruminative Response 
Scale   * p < .05.    ** p < .001. 
 
  
	  	  
77 
Table 10.  Means and standard deviations for response time on Internal Shift Task (IST) 
Trials 
 
 Baseline 
Mean (SD) 
Week 3 
Mean (SD) 
Week 5 
Mean (SD) 
Week 8 
Mean (SD) 
Emotion 
Condition 
    
Non-Switch 1249.29 (421.51) 1006.78 (292.70) 956.59 (306.42) 956.13 (207.30) 
Switch 1584.35 (488.32) 1353.69 (416.75) 1224.27 (353.36) 1230.25 (291.98) 
Gender 
Condition 
    
Non-Switch 1052.17 (314.09) 921.58 (229.04) 872.75 (191.72) 844.10 (193.96) 
Switch 1419.70 (406.10) 1234.66 (342.44) 1108.42 (300.25) 1082.23 (325.58) 
Emotion Switch 
Cost 
335.06 (191.80) 346.92 (187.06) 267.68 (193.45) 274.13 (186.28) 
Gender Switch 
Cost 
367.52 (217.68) 313.08 (230.25) 235.67 (193.80) 238.125 (218.28) 
Note. All results reported in milliseconds.  Emotion and Gender Switch Cost scores were 
calculated as the difference between average response time for switch and non-switch trials in  
the emotion and gender conditions, respectively. 
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Table 11.  Hierarchical multiple regression analyses of the predictive influence of 
baseline IST emotion switch cost and treatment condition on week 8 treatment outcomes. 
 B t p Model R2  
BDI week 8     
Step 1    .26 
     BDI week 1 .69 2.71* .01  
Step 2    .29 
     Emotion switch cost week 1 -.01 -0.55 .59  
     Treatment Condition 2.12 0.87 .40  
Step 3    .34 
     Condition X Emotion Switch cost  .02 1.13 .27  
     
MADRS week 8     
Step 1    .43 
     MADRS week 1 1.00 4.00** .00  
Step 2    .44 
     Emotion switch cost week 1 .00 0.27 .79  
     Treatment Condition .58 0.35 .73  
Step 3    .45 
     Condition X Emotion Switch cost  .01 0.67 .51  
     
RRS-brooding week 8     
Step 1    .24 
     RRS-brooding week 1 .60 2.61* .02  
Step 2    .32 
     Emotion switch cost week 1 .00 0.28 .78  
     Treatment Condition .93 1.41 .18  
Step 3    .39 
     Condition X Emotion Switch cost  .01 1.48 .16  
     RRS-reflection week 8     
Step 1    .43 
     RRS-reflection week 1 .66 3.99** .00  
Step 2    .54 
     Emotion switch cost week 1 -.01 -1.75 .10  
     Treatment Condition .89 1.65 .12  
Step 3    .55 
     Condition X Emotion Switch cost  .00 0.69 .50  
Note.  BDI = Beck Depression Inventory-II; NAP = Negative Affective Priming task; MADRS = 
Montgomery-Asberg Depression Rating Scale; RRS-brooding = Brooding subscale of  
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the Ruminative Response Scale; RRS-reflection = Reflection subscale of the Ruminative  
Response Scale   * p < .05. ** p < .001 
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FIGURES 
      Figure 1.  CONSORT diagram of participant enrollment. 
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   Excluded (n = 26) Reasons for 
exclusion: 
Not depressed (n=7) 
Bipolar Disorder or 
Psychosis (n = 11) 
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Current alcohol or 
drug dependence (n = 
2) 
Over age 65 (n = 1) 
 
 
Scheduled for screening 
visit (n = 52) 
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visit (n = 9) 
Excluded (n = 6) 
Reasons for 
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than MDD (n = 1) 
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Figure 2.  Negative Affective Priming Task: Example of a priming trial (in the negative 
information condition)   
 
 
 
500 ms 
 
 
 
 
 
 
 
 
       500 ms 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note.  In a negative priming trial, the prime trial distractor (the red word) shares  
the same valence as the test trial target (the blue word).  The negative priming  
trial can be negative (i.e., the prime trial distractor and test trial targets are  
negatively valenced) or positive (i.e., the prime trial distractor and test trial targets  
are positively valenced). 
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Figure 3.  Negative Affective Priming Task: Example of a control trial.   
 
 
 
500 ms 
 
 
 
 
 
 
 
 
     500 ms 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note.  In a control condition trial, the prime trial distractor (the red word) is  
neutrally valenced and does not share the same valence as the test trial target  
(the blue word, which is either negative or positive).  The control trial can be  
negative (i.e., the test trial target is negatively valenced) or positive (i.e., the test  
trial targets is positively valenced). 
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Figure 4.  NAP-Positive Scores over time by treatment condition. 
  
 
 
Note.  CCT = Cognitive Control Training; PVT = Peripheral Vision Training 
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